Lysine-specific histone demethylase 1 (LSD1) : A novel molecular target for tumor therapy by Lim, Soyoung
 
 
 
 
Lysine-specific histone demethylase 1 (LSD1): 
A novel molecular target for tumor therapy 
 
 
Thesis 
 
 
Submitted for a Doctoral Degree  
in Natural Sciences (Dr. rer.nat.) 
Mathematics and Natural Sciences Faculty 
Rheinische Friedrich Wilhelms University, Bonn 
 
 
 
Submitted by 
Soyoung Lim 
from  
South Korea 
 
 
Bonn, 2009 
 
 Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen 
Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supervisor:   Prof. Dr. Reinhard Büttner 
First reviewer:  Prof. Dr. Christa E. Müller 
Second reviewer:  Prof. Dr. Evi Kostenis 
Third reviewer:  Prof. Dr. Hubert Schorle 
 
 
 
Date of Submission: 14. Jul. 2009 
Date of Examination: 12. Nov. 2009 
 
 
 
 
 
  
 
 
Declaration 
 
 
 
I solemnly declare that the work submitted here is the result of my own 
investigation, except where otherwise stated. This work has not been submitted 
to any other university or institute towards the partial fulfillment of any degree.  
 
 
 
Soyoung Lim 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of contents 
 
 i 
Table of contents 
 
Table of contents ..............................................................................................................i 
Summary........................................................................................................................vi 
Abbreviations................................................................................................................ viii 
1.   Introduction............................................................................................................... 1 
1.1.   What is epigenetics?.......................................................................................... 1 
1.2.   Chromatin structure ........................................................................................... 1 
1.3.   DNA methylation................................................................................................ 3 
1.4.   Histone modifications......................................................................................... 4 
1.4.1.   Acetylation of histones ................................................................................ 7 
1.4.2.   Lysine methylation ...................................................................................... 7 
1.4.3.   Arginine methylation, phosphorylation and ubiquitination ............................ 8 
1.5.   Interpretation of epigenetic modifications ........................................................... 9 
1.6.   Lysine-specific histone demethylase 1 (LSD1)................................................. 12 
1.6.1.   Linking LSD1 to gene repression .............................................................. 14 
1.6.2.   The role of LSD1 in gene activation .......................................................... 15 
1.6.3.   The role of LSD1 in development and differentiation................................. 16 
1.6.4.   LSD1 functions beyond histone demethylation.......................................... 17 
1.7.   Altered epigenetic modifications in cancer ....................................................... 17 
1.8.   Epigenetic therapy of cancer............................................................................ 19 
1.8.1.   DNMT and HDAC inhibitors ...................................................................... 19 
1.8.2.   Targeting LSD1 in tumor therapy .............................................................. 20 
2.   Aims of this work .................................................................................................... 22 
3.   LSD1 in neuroblastoma .......................................................................................... 23 
3.1.   Neuroblastoma ................................................................................................ 23 
3.2.   Results............................................................................................................. 25 
3.2.1.   LSD1 is strongly expressed in poorly differentiated neuroblastomas......... 25 
3.2.2.   LSD1 expression in neuroblastoma cell lines ............................................ 27 
3.2.3.   Silencing of LSD1 impairs neuroblastoma growth and induces cellular 
differentiation in vitro............................................................................................. 28 
3.2.4.   Knock-down of LSD1 upregulates putative tumor suppressor genes and 
alters gene specific H3K4 methylation .................................................................. 30 
3.2.5.   LSD1 inhibition using MAOIs impairs neuroblastoma growth in vitro ......... 32 
Table of contents 
 
 ii 
3.2.6.   Small molecule inhibitor of LSD1 inhibits xenograft tumor growth ............. 33 
4.   LSD1 in breast cancer ............................................................................................ 35 
4.1.   Breast cancer................................................................................................... 35 
4.2.   Results............................................................................................................. 37 
4.2.1.   Development of LSD1 ELISA .................................................................... 37 
4.2.2.   LSD1 is strongly expressed in ER-negative breast cancer ........................ 39 
4.2.3.   LSD1 inhibition using MAOIs confers growth inhibition and increase of 
global H3K4 methylation in vitro............................................................................ 41 
4.2.4.   siRNA-mediated knock down of LSD1 reduces cellular growth ................. 43 
4.2.5.   Knock-down of LSD1 induces downregulation of proliferation associated 
genes and alters target gene-specific H3K9 methylation....................................... 44 
5.   LSD1 enzyme assay for high-throughput screening (HTS) ..................................... 47 
5.1.   Epi-drugs, a new class of cancer therapeutics ................................................. 47 
5.2.   Results............................................................................................................. 48 
5.2.1.   Cloning and expression of recombinant human LSD1............................... 48 
5.2.2.   Establishment of LSD1-HRP coupled assay for high-throughput screening49 
5.2.3.   Chemical screening for LSD1 inhibitors..................................................... 53 
6.   Discussion .............................................................................................................. 57 
6.1.   LSD1 in neuroblastoma.................................................................................... 57 
6.1.1.   LSD1 expression correlates with cell differentiation and growth in 
neuroblastoma...................................................................................................... 57 
6.1.2.   Specificity and regulatory mechanism of LSD1 are cellular complex 
dependent............................................................................................................. 57 
6.1.3.   Epigenetic therapy may serve as an alternative to targeting transcription 
factors................................................................................................................... 58 
6.1.4.   Do MAO inhibitors qualify as LSD1 inhibitors in a clinical setting?............. 58 
6.1.5.   Multimodal epigenetic therapy might be applicable as targeted therapy.... 59 
6.2.   LSD1 in breast cancer ..................................................................................... 60 
6.2.1.   Establishment of an ELISA for screening LSD1 levels in tumor tissues..... 60 
6.2.2.   LSD1 is highly expressed in hormone receptor-negative breast cancers... 60 
6.2.3.   LSD1 contributes to cell proliferation through regulation of CCNA2 and 
ERBB2.................................................................................................................. 61 
6.2.4.   LSD1 functions in association with other transcriptional cofactors/epigenetic 
enzymes ............................................................................................................... 62 
Table of contents 
 
 iii 
6.2.5.   Targeting LSD1 in breast cancer provides a novel therapeutic option ....... 62 
6.3.   LSD1 enzyme assay for high-throughput ......................................................... 64 
6.3.1.   The LSD1-HRP coupled assay can be applied for high-throughput kinetic 
study..................................................................................................................... 64 
6.3.2.   The LSD1-HRP coupled assay identified a putative LSD1 inhibitor ........... 65 
6.3.3.   Is LSD1 a promising drug target for cancer therapy? ................................ 65 
6.3.4.   Epigenetic therapy can be used in combination with other therapeutic 
modalities. ............................................................................................................ 66 
7.   Materials and methods ........................................................................................... 67 
7.1.   Material............................................................................................................ 67 
7.1.1.   Chemicals ................................................................................................. 67 
7.1.2.   Apparatus ..................................................................................................... 68 
7.1.3.   Consumables............................................................................................ 69 
7.1.4.   Antibodies ................................................................................................. 70 
7.1.5.   Kits............................................................................................................ 70 
7.1.6.   Enzymes and markers .............................................................................. 70 
7.1.7.   Vectors...................................................................................................... 71 
7.1.8.   Primer sequences ..................................................................................... 71 
7.1.9.   Bacterial strains ........................................................................................ 72 
7.1.10.   Cell lines ................................................................................................. 73 
7.1.11.   Human breast specimens........................................................................ 73 
7.2.   Buffers and solutions ....................................................................................... 73 
7.2.1.   Bacterial culture ........................................................................................ 73 
7.2.2.   Cell culture................................................................................................ 74 
7.2.3.   Protein expression & purification............................................................... 74 
7.2.4.   Western blotting ........................................................................................ 74 
7.2.5.   DNA/RNA techniques................................................................................ 75 
7.3.   Cell culture techniques for mammalian cells .................................................... 75 
7.3.1.   Mammalian cell culture method................................................................. 75 
7.3.2.   Freezing and thawing of mammalian cells................................................. 76 
7.3.3.   Treatment of adherent cells with siRNAs................................................... 76 
7.3.4.   Treatment of adherent cell with MAOIs ..................................................... 76 
7.3.5.   MTT cell proliferation assay ...................................................................... 76 
7.4.   DNA techniques............................................................................................... 77 
Table of contents 
 
 iv 
7.4.1.   Photometric measurement of nucleic acid concentration........................... 77 
7.4.2.   Plasmid DNA isolation (mini/maxi preparation).......................................... 77 
7.4.3.   Separation of DNA by agarose gel electrophoresis ................................... 77 
7.4.4.   Extraction of DNA from agarose gels ........................................................ 78 
7.4.5.   DNA precipitation in ethanol/isopropanol................................................... 78 
7.4.6.   Enzymatic restriction of plasmids .............................................................. 78 
7.4.7.   Dephosphorylation of DNA fragments ....................................................... 78 
7.4.8.   Ligation of DNA fragments ........................................................................ 78 
7.4.9.   Ligation of PCR products/TOPO cloning ................................................... 79 
7.4.10.   Transformation and selection .................................................................. 79 
7.4.11.   Cloning of LSD1 expression construct..................................................... 79 
7.4.12.   Sequencing of DNA................................................................................. 79 
7.4.13.   Sequence analysis .................................................................................. 79 
7.4.14.   PCR: in vitro amplification of DNA........................................................... 80 
7.4.15.   Purification of PCR-Products................................................................... 80 
7.4.16.   Real-time RT-PCR .................................................................................. 81 
7.4.17.   Chromatin Immunoprecipitaiton............................................................... 81 
7.5.   RNA techniques............................................................................................... 82 
7.5.1.   Isolation of RNA........................................................................................ 82 
7.5.2.   Reverse transcription/cDNA synthesis ...................................................... 82 
7.6.   Protein techniques ........................................................................................... 82 
7.6.1.   Preparation of protein samples from adherent cells .................................. 82 
7.6.2.   Preparation of protein samples from tissues ............................................. 82 
7.6.3.   Tissue preparation – Cryosectioning ......................................................... 83 
7.6.4.   Hematoxylin and Eosin (HE) staining ........................................................ 83 
7.6.5.   Immunohistochemistry .............................................................................. 83 
7.6.6.   Protein quantification................................................................................. 84 
7.6.7.   Protein staining with Coomassie Brilliant Blue R250 ................................. 84 
7.6.8.   SDS-PAGE/Western blot .......................................................................... 84 
7.6.9.   ELISA ....................................................................................................... 85 
7.6.10.   Expression and purification of recombinant human LSD1 ....................... 85 
7.6.11.   LSD1 enzyme assay for high-throughput screening ................................ 86 
7.6.12.   in vitro demethylase assay ...................................................................... 87 
7.7.   Growth of xenograft tumors in nude mice......................................................... 87 
Table of contents 
 
 v 
7.8.   Statistical methods........................................................................................... 87 
8.   Reference............................................................................................................... 88 
9.   Acknowledgements................................................................................................. 95 
10.   Curriculum Vitae ................................................................................................... 96 
11.   Appendix .............................................................................................................. 98 
Summary 
 
 vi 
Summary 
 
 
Aberrant epigenetic changes in DNA methylation and histone acetylation are hallmarks 
of most cancers, while histone methylation had been considered to be irreversible and 
less versatile. Recently, several histone demethylases were identified catalyzing the 
removal of methyl groups from histone H3 lysine residues and thereby influencing gene 
expression. Lysine-specific histone demethylase 1 (LSD1) modulates demethylation of 
mono- and dimethylated lysines at residues 4 or 9 in histone H3, thereby allowing 
transcription factors or co-repressor complexes to selectively initiate or repress 
transcription. Although the physiological role of histone methylation is actively 
investigated, little is known about the implication of LSD1 in tumorigenesis. Here, we 
addressed the functional significance of LSD1 in different tumor types. 
 
Neuroblastoma is the most common extracranial tumor of childhood originating from 
undifferentiated precursor cells of the peripheral sympathetic nervous system. Despite 
advances in multimodal therapy, neuroblastomas remain a clinical challenge. In this 
work, we found that LSD1 is strongly expressed in very aggressive neuroblastomas. 
LSD1 expression was inversely correlated with differentiation in primary neuroblastic 
tumors and correlated with adverse clinical outcome. In vitro differentiation of 
neuroblastoma cells resulted in downregulation of LSD1, suggesting that LSD1 is 
involved in maintaining the undifferentiated, malignant phenotype of neuroblastoma cells. 
siRNA-mediated knock-down of LSD1 decreased cellular growth and induced 
expression of differentiation-associated genes like TNS1, TPM1, DNM2 and DNAL4. 
Upon knock-down of LSD1, putative tumor suppressor genes like TFPI2 and XRCC5 
were increased accompanied by the increase in target gene specific H3K4 methylation. 
Since the catalytic domain of LSD1 has a high sequence homology to 
monoaminoxidases (MAOs), MAO inhibitors (MAOIs) were reported as LSD1 inhibitors. 
LSD1 inhibition using MAOIs resulted in an increase of global H3K4 methylation and 
growth inhibition of neuroblastoma cells in vitro. A xenograft mouse model was used to 
assess the potential therapeutic value of targeting LSD1 in neuroblastic tumor in vivo. 
For the first time, we could show that the treatment with MAOI tranylcypromine reduced 
significantly xenograft tumor growth, suggesting that LSD1 may serve as a drug target in 
neuroblastoma. However, MAOIs were shown to be inadequate for tumor treatment due 
Summary 
 
 vii 
to their excessive side effects such as seizures caused by their modulation of 
neurotransmitter deamination. Instead, specific LSD1 inhibitors must be developed 
which do not inhibit type A and B MAOs.  
 
In industrialized countries, breast cancer is the most common tumor in women. 
Expression level of estrogen receptors (ERs) is an important predictive diagnostic 
marker indicating a favourable clinical course and response to hormone therapy. In this 
work, I developed an ELISA to examine LSD1 protein levels in tissue specimens of 
breast cancer. We determined very high LSD1 expression in ER-negative tumors which 
are known to have a poorer prognosis than ER-positive tumors. Pharmacological LSD1 
inhibition resulted in growth inhibition of breast cancer cells. Genetic knock-down of 
LSD1 induced downregulation of proliferation-associated genes such as CCNA2 and 
ERBB2 and increased target gene-specific H3K9 methylation. These data indicate that 
LSD1 may serve as a predictive marker for aggressive biology and targeting LSD1 in 
ER-negative breast cancers might provide more specific treatment. 
In summary, I could show that LSD1 is strongly expressed in malignant neuroblastoma 
and breast cancer and functions as an oncogene. 
 
Although histone methylation has been shown to be implicated in tumorigenesis, to date, 
no specific chemical modulator of LSD1 has been described. To identify selective LSD1 
inhibitors from a compound library comprising 768 compounds selected by 
cheminformatics approach, a LSD1-HRP coupled assay was developed and applied for 
a high-throughput kinetic study. In this screening, a putative LSD1 inhibitor was identified 
and further experiments are going on to evaluate its LSD1 inhibitory actions. The 
identification of a new LSD1 inhibitor may serve as a starting point toward the 
development of a new class of LSD1 inhibitors which would help to evaluate the 
therapeutic potential of targeting LSD1 for tumor therapy. 
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1.   Introduction 
 
 
1.1.   What is epigenetics?  
 
Epigenetics is defined as heritable changes in gene activity and expression that occur 
without alteration in DNA sequence (Goldberg et al., 2007; Bird 2007). The best example 
of an epigenetic change is the differentiation process in which cells carrying identical 
DNA differentiate into different cell type. Genomic imprinting which results in monoallelic 
expression or X chromosome inactivation in female mammalian cells are also referred to 
the epigenetic phenomena. Epigenetic changes are preserved when cells divide 
(Jaenisch, 2008). Thus, epigenetics is considered a bridge between genotype and 
phenotype (Bernstein et al., 2007; Jaenisch et al., 2003; Reik, 2007).  
Different epigenetic phenomena are linked largely by the fact that DNA is not “naked” but 
exists as an intimate complex with histones (and histone variants) and other chromatin-
related proteins such as chromatin remodeling proteins. Mainly, epigenetic information is 
stored as chemical modifications to cytosine bases and to the histone protein. These 
chemical changes regulate chromatin structure and DNA accessibility. Small non-coding 
RNAs also play an important role in targeting chromatin-modifying effectors to the 
specific chromatin loci. In the last decade, epigenetic processes were known to be 
fundamental to normal development and they are increasingly recognized as being 
involved in human diseases (Ozanne et al., 2007; Feinberg et al., 2004; Esteller, 2008). 
Here, two main epigenetic modifications, DNA methylation and histone modifications are 
discussed in detail with emphasis on their roles in transcription.  
 
 
1.2.   Chromatin structure 
 
Genomic DNA in eukaryotic cells is packaged with histones to form protein/DNA 
complexes called chromatin. The basic unit of chromatin is the nucleosome, which is 
composed of ~147 base pairs of DNA wrapped around an octamer of the four core 
histones (H2A, H2B, H3, and H4) (Figure 1.1). The core histones are tightly packed in 
globular regions with amino-terminal tails that extend from the globular region, making 
them accessible to histone modifying enzymes (Luger et al., 1997) (Figure 1.1). Another 
protein, termed linker histone H1, interacts with DNA links between nucleosomes. It 
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functions in the compaction of chromatin into higher-order structures that comprise 
chromosomes.  
 
 
 
In a non-dividing cell, chromatin can be divided into two functional states: euchromatin or 
heterochromatin. Euchromatin accounting for a less than 4 % of the genome is the 
region where DNA is accessible, representing an open conformation due to the relaxed 
state of nucleosome arrangement. Euchromatin contains genes in active and inactive 
transcriptional states (Koch et al., 2007). Some of the genes are ubiquitously expressed 
(housekeeping genes); others are developmentally regulated or stress-induced in 
response to environmental cues.  
Conversely, heterochromatin comprising 95 % of the genome constitutes an area where 
DNA is packaged into highly condensed forms that are inaccessible to transcription 
factors or chromatin-associated proteins (Jenuwein et al., 2001; Talbert et al., 2006; 
Huang et al., 2004). Heterochromatin primarily consists of noncoding and repetitive 
sequences and the repressed genes associated with morphogenesis or differentiation 
(imprinting or X chromosome inactivation) (Reik, 2007; Feinberg et al., 2004). 
A B 
Figure 1.1. Higher order structuring of 
chromatin and structure of 
nucleosome.  (A) DNA is compacked 
with core histones (red) forming 
chromatin. Linker Histone H1 (yellow) 
functions in compaction of chromatin into 
higher order chromosomes. (Picture from 
www.epitron.eu)   
(B) Nucleosome, the basic unit of 
chromatin, is composed of 146 base pairs 
of DNA (black) wrapped around an 
octamer of the four core histones. The 
amino-terminal tails extrude from the 
nucleosome core.  
H3
H4
H4
H2AH2A
H2B
H3
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Heterochromatin has critical functions in controlling chromosomal stability and the 
prevention of mutations and translocations (Muegge, 2005; Huang et al., 2004). 
 
 
1.3.   DNA methylation  
 
DNA methylation is the first recognized and most well-characterized epigenetic 
modification.  In mammalian cells, DNA methylation occurs at the 5´ position of the 
cytosine ring within CpG dinucleotides via addition of a methyl group to create a 5-
methylcytosine (m5C) (Figure 1.2). Three mammalian DNA methyltransferases (DNMTs) 
have been described (Chen et al., 2004; Bestor, 2000).  DNMT3a and DNMT3b function 
primarily as “de novo” methyltransferases, targeting unmethylated CpGs to initiate 
methylation. The process of de novo methylation can occur in early embryonic stem cells 
or cancer cells (Okano et al., 1999). In contrast, DNMT1 acts as a “maintenance” 
methyltransferase, which has specificity for hemi-methylated CpG dinucleotides. After 
DNA replication, DNMT1 recognizes hemi-methylated CpGs and copies DNA 
methylation patterns to a newly synthesized DNA strand based on the DNA methylation 
pattern in the complementary template strand. By this process DNA methylation patterns 
can be inherited through DNA replication (Groth et al., 2007; Li et al., 1992). 
 
 
 
Figure 1.2. The formation of 5-methylcytosine. Using S-adenosyl methionine as a methyl 
group donor, DNMT catalyzes the methylation reaction of cytosine. 
 
DNMT
Cytosine 5-Methylcytosine
S-Adenosyl
Methionine
Homocysteine
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CpGs tend to cluster in regions termed CpG islands (CpGIs). CpGIs are characterized 
by more than 50% (G+C) and CpG content, spanning at least 200 bases. On a genome 
scale, methylated DNA is enriched at noncoding regions (e.g., centromeric 
heterochromatin) and interspersed at repetitive elements (transposons), thus linked to 
transcriptional silencing and formation of heterochromatin (Feinberg et al., 2004). In 
euchromatin, CpGIs are found at 60% of the 5´ends of many genes. CpG methylation at 
the gene promoter-associated regions is believed critical for the control of gene silencing 
(Muegge, 2005; Huang et al., 2004). The 5` regions of genes involved in imprinting, X 
chromosome inactivation, and tissue-specific differentiation are hypermethylated, while 
the 5` regions of most housekeeping genes and many regulated genes are frequently 
unmethylated, remaining accessible to transcription factors and chromatin-associated 
proteins (Jones et al., 2007; Laird, 2003).  
 
 
1.4.   Histone modifications  
 
 
 
 
 
Figure 1.3. Post-translational modifications of the core histones. Histone methylation at 
lysines is represented as green pentagons and phosphorylation at serines or threonines as 
yellow circles, upiquitination as blue stars and acetylation at lysines as red triangles (Peterson et 
al., 2004). 
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The N-terminals of the core histones are subjected to several types of post-translational 
modifications, including acetylation, methylation, phosphorylation, ubiquitination and 
sumoylation (Kouzarides, 2007; Ruthenburg et al., 2007) (Figure 1.3). Site-specific 
combinations of histone modifications termed “histone code” correlated well with 
particular biological functions, such as transcriptional activation/repression, DNA 
replication, DNA repair, histone deposition, mitosis/meiosis, formation of 
euchromatin/heterochromatin and X inactivation (Peterson et al., 2004). In contrast to 
DNA methylation, which is relatively stable, histone modifications are more dynamic 
responding to hormonal signals, environmental factors or drug treatment (Jones et al., 
2005).   
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(Kourarides, 2007; Peterson et al., 2004; Li et al., 2007) 
 
 
Table 1.1.  Chromatin modification  
 
 
Modification 
 
Position 
 
Enzymes  Transcriptional role 
 
DNA methylation 
 
  Methyltransferase   
Methylated 
cytosine 
CpG islands DNMT 1-3  Repression 
 
Histone modifications 
 
 
 
 
 
 
 
Lys methylation  Lysine 
methyltransferase 
Lysine 
demethylase 
 
H3 K4 MLL, ALL-1, Set9/7, 
ALR-1/2, ALR, Set1, 
ASH1 
LSD1, Jarid1A-D Activation 
H3 K9 Suv39h, G9a, Eu-
HMTase I, 
ESET/SETBD1 
LSD1/AR, JHDM2A, 
JMJD2A-D 
Repression, 
Activation 
H3 K27 EZH2 UTX, JMJD3 Repression 
H3 K36 HYPB, Smyd2, NSD1, 
Set2 
JHDM1, JMJD2A-C, 
FBXL10 
Elongation 
Recruiting the Rpd3S 
to repress internal  
initiation 
H3 K79 Dot1  Activation 
 
H4 K20 PR-Set7, SET8  Silencing 
Arg methylation 
 
 Arginine 
methyltransferase 
Arginine demethylase  
 H3 R2/17/26 CARM1 Not found Activation 
 H4 R3 PRMT1   
Phosphorylation  Ser/Thr kinase  Phosphatase  
 H3 S10   Activation 
Acetylation  Acetyltransferase Deacetylase  
 H3 K9 PCAF/GCN5,  
 H3 K14 PCAF/GCN5, 
CBP/p300, TIP60, 
ScSAS3 
 H3 K18 PCAF/GCN5,  
CBP/p300 
 H3 K23 ScSAS3 
 H3 K56 ScRTT109 
 H4 K5 CBP/p300, HAT1, 
TIP60, HB01 
 H4 K8 CBP/p300,  
TIP60, HB01 
 H4 K12 TIP60, HB01, HAT1 
HDACs show no 
specificity for a 
particular aectyl 
group, except SirT2. 
(Kouzarides et al., 
2007) 
 H4 K16 TIP60, ScSAS2 SirT2 
 H2A K5 CBP/p300 
 H2B K12 CBP/p300 
 H2B K15 CBP/p300 
 
Activation 
Ubiquitination  Ubiquitin ligase   
 H2B K120 UbcH6, RNF20/40  Activation 
 H2A K119 hPRC1L/Bmi/Ring1A  Repression 
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1.4.1.   Acetylation of histones  
 
In 1996, the first nuclear histone acetyltransferase (HAT) Gca5 was identified which had 
previously been characterized as a transcriptional co-activator protein. Subsequently, a 
variety of other transcriptional co-activators, such as CBP/p300 were found to have 
intrinsic HAT activity, and many co-repressors, such as Rpd3, were found to have 
histone deacetylase (HDAC) activity (Peterson et al., 2004).  
Acetylation of lysine residues at the N-terminus of histone tails is connected with 
transcriptional activation by directly affecting chromatin structure (Feinberg et al., 2004). 
Acetylation removes positive charges of the lysine residues and reduces the affinity 
between histones and negatively charged DNA, thereby opening the condensed 
chromatin structure to allow transcriptional machinery easier access to promoter regions. 
Thus, histone acetylation relies primarily on the number of lysines modified, which is 
termed a cumulative effect (Li et al., 2007). The known acetylation sites and HAT/HDAC 
enzymes are summarized in table 1.1.  
 
 
1.4.2.   Lysine methylation  
 
While acetylation is positively correlated with actively transcribed genes (Roh et al., 
2005) methylation can either activate or repress transcription, depending upon the site 
and degree (mono-, di-, and trimethylation) of modifications (Ruthenburg et al., 2007). In 
contrast to acetylation, histone methylations are regulated with enormous specificity. 
One histone methyltransferase (HMT) modifies one single lysine on a single histone 
(Kuzarides, 2007). Histone methylation had been thought of as an irreversible epigenetic 
mark until the first lysine specific histone demethylase LSD1 (also known as AOF2 and 
KDM1) was discovered in 2004 (Shi et al., 2004). Subsequent to the discovery of LSD1, 
another family of more than 30 histone demethylases structurally different from LSD1 
was described, all of which sharing a motif designated the Jumonji C (JmjC) domain and 
revealing a substrate specificity. Identification of these enzymes opened a new era in 
understanding how chromatin dynamic is regulated and further understanding of the 
regulation of these enzymes will provide significant insight into fundamental mechanisms 
of many biological processes and human diseases. Currently known site-specific HMTs 
and histone lysine demethylases (KDMs) are listed in table 1.1.    
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Six lysine (K) residues on histone H3 and H4 (H3K4, H3K9, H3K27, H3K36, H3K79 and 
H4K20) are subjected to mono-, di- and tri-methylation. Importantly each methylation 
state represent a specific epigenetic mark with a precise biological meaning and well-
defined chromatin localization (Figure 1.3) (Margueron et al., 2005). H3K4, H3K36 and 
H3K79 are implicated in activation of transcription, whereas H3K9, H3K27 and H4K20 
are connected to transcriptional repression. 
 
 
1.4.3.   Arginine methylation, phosphorylation and ubiquitination 
 
In contrast to lysine acetylation and methylation, the function of the following three 
histone modifications has not been fully elucidated yet. Arginine methylation can be 
either activatory or repressive for transcription. Arginine methylation is mediated by 
arginine methyltransferases (PRMTs), but there are no enzymes yet identified that can 
reverse arginine methylation (Kouzarides, 2007).  
Ubiquitination is a very large modification and has been found on H2A (K119) and H2B 
(K120). Ubiquitylation of H2AK119 is mediated by the Bmi/Ring1A protein and is 
associated with transcriptional repression. In contrast, H2BK120 ubiquitylation is 
mediated by RNF20/RNF40 and activates transcription. 
Little is known about phosphorylation and gene expression. A role for H3S10 
phosphorylation has been demonstrated for the activation of “immediate early” genes. 
For example, concomitant with this phosphorylation, a phosphor-binding protein 14-3-3 
was shown to appear on chromatin (Kourarides, 2007).  
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1.5.   Interpretation of epigenetic modifications  
 
The global genome-analyses revealed that distribution of histones and histone 
modifications correlates with transcription state (Figure 1.4). In activated gene regions, 
there is an enrichment of active histone markers such as methylation at H3K4, H3K36, 
or H3K79 and global acetylation at core histone (Koch et al., 2007; Heintzman et al., 
2007; Edmunds et al., 2008; Steger et al., 2008; Krivtsov et al., 2008). “Tri or di-
methylation” at H3K4 and H3/H4ac are heavily enriched around the transcriptional start  
 
 
 
                                      
 
 
Figure 1.4. Genome-wide distribution pattern of histone modification from a transcription 
perspective. The distribution of histones and their modifications are illustrated on an arbitrary gene 
relative to its promoter. The location of a modification is tightly regulated with distinct patterns within 
the upstream region, the core promoter, the 5´ end of the open reading frame (ORF) and the 3´end 
of the ORF. This distribution of modifications is crucial for its effect on transcription. Acetylation of 
histone 3 and histone 4 or di- or trimethylation of H3K4, are associated with active transcription, 
whereas, modifications, such as H3K9me and H3K27me, are localized to inactive genes or regions 
termed heterochromatin (Li et al., 2007). 
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sites, while methylation at H3K36 and H3K79 are distributed downstream of activated 
gene regions. H3K36me3 at the 3´end of active genes was found to have a function in 
the suppression of inappropriate initiation from cryptic start sites within the coding region 
(Kuzarides, 2007). Moreover, histone H2A is replaced with histone variant H2A.Z around 
the transcriptional start sites. In contrast, for genes that are not expressed or are 
expressed at low levels, high levels of repressive histone markers such as H3K27me2 
and H3K9me2/3 are enriched around the transcriptional start sites.  
 
Histone modifications occur in a combinatorial manner. The transition of a naive 
chromatin template to active euchromatin or establishment of repressive 
heterochromatin involves a series of coordinated chromatin modifications. As shown in 
figure 1.5, combinations of active marks are progressively induced while simultanously 
Signals
Naive chromatin
Active chromatin
Repressed chromatin
H2B K123ub
H3K79me
H3K4me H3K9me
H3K9acHP1
H2R17me
H4K16ac
H4K20me
H3K9me H3K9ac
HP1 H3S10ph
H4K20me
DNA methylation
H4K16ac
Recruitment of nucleosome-remodeling complexes
Replacement of core histones with histone variants
Figure 1.5. Coordinated modification of chromatin. The transition of a naive 
chromatin template to active euchromatin or establishment of repressive heterochromatin 
involves a series of coordinated chromatin modifications. Active marks are represented 
as red, and repressive marks as blue (modified from Allis et al., 2007). 
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counteracting repressive modifications (Allis et al., 2007). Especially, histone lysine 
methylation has been linked to DNA methylation and is thus implicated in gene silencing.  
 
Once the “histone code” is established at a given locus, then how can this epigenetic 
information be interpreted to bring biological consequences? Some “effector” proteins 
have been reported that can recognize these specific histone modifications and bind to 
the modified histone tails (Figure 1.6) (Allis et al., 2007). For example, proteins that have 
chromodomains bind to methylated lysines, whereas bromodomains within proteins 
specifically bind to acetylated lysines. Heterochromatin protein 1 (HP1) which has a 
chromodomain interacts specifically with dimethylated H3K9, leading to the silencing of 
euchromatic genes as well as the formation of silent heterochromatin (Figure 1.5 and 
1.6). The chromodomain within the Polycomb protein binds specifically to a dimethylated 
K27 of histone H3, resulting in the silencing of the homeobox protein (HOX) gene 
expression (Figure 1.6). The binding of bromodomains to different acetylated lysines, 
however, does not show as much specificity. In the case of DNA methylation, methyl-
CpG-binding domain proteins (MBD) are considered the “reader/binder” of DNA 
methylation, functioning in silencing of chromatin (Figure 1.6). 
 
 
 
 
Figure 1.6. From epigenetic modification to biological consequences. “Effector” proteins can 
recognize specific histone modification. Chromodomains within proteins bind to methylated lysine 
and bromodomains within proteins bind to acetylated lysine.  There are no protein domains yet 
identified that can bind specifically to arginine-methylated histones or serine/threonine-
phosphorylated histones. 
Ac
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Chromodomain
(e.g. HP1  H3K9me
polycomb  H3K27me)
Me
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1.6.   Lysine-specific histone demethylase 1 (LSD1) 
 
It was recently demonstrated that methylation marks are not static but dynamically 
regulated by both histone methyltransferases and histone demethylases. LSD1 is the 
first discovered histone demethylase which catalyzes the demethylation reaction of 
mono- and dimethylated histone H3 lysine 4 (Shi et al., 2004). LSD1 is highly conserved 
in organisms ranging from Schizosaccharomyces pombe to human and consists of three 
major domains: an N-terminal SWIRM (Swi3p/Rsc8p/Moira) domain, a C-terminal AOL 
(amine oxidase-like) domain, and a central protruding Tower domain (Figure 1.7). The 
C-terminal catalytic domain reveals high sequence homology to amine oxidases 
 
 
Figure 1.7. Structure of human LSD1. (A) Domain structure. Gray, unstructured N-terminal 
region; yellow, SWIRM domain; red, SWIRM-oxidase connector; blue, oxidase domain; green, 
helical insertion (Stavropoulos et al., 2006).  (B) Structure of LSD1 in complex with CoREST and 
a peptide substrate. LSD1 (blue) tightly associates with the CoREST C-terminal SANT domain 
(red). The histone H3 N-terminal peptide (residues 1-16; green) binds in the LSD1 amine oxidase 
domain in proximity to the flavin cofactor (yellow) (Forneris et al., 2008). 
 
A
B
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that belong to the flavin adenine dinucleotide (FAD)-dependent enzyme family including 
mono- and polyaminoxidase. The N-terminal SWIRM domain seems to be important for 
chromatin binding (Anand et al., 2007). The Tower domain, inserted into the AOL 
domain, forms a long helix-turn-helix structure and serves as a platform for binding of 
LSD1 partner proteins such as corepresser element silencing factor, CoREST.   
 
LSD1 acts on mono- and dimethylated H3K4 through a flavin-dependent mechanism 
(Shi et al., 2004; Forneris et al., 2005). The reaction results in a hybrid transfer with 
reduction of FAD to FADH2 which is reoxidized by molecular oxygen, producing 
hydrogen peroxide (Figure 1.8). The resulting imine intermediate is hydrolyzed to 
generate the demethylated H3 tail and formaldehyde. LSD1 cannot demethylate 
trimethylated lysine residues, since a lone pair of electrons in the unprotonated state of 
N of methylated lysine is required in FAD-mediated reaction. Forneris et al. showed that 
LSD1 requires the first 20 N-terminal amino acids of the histone tail for productive 
binding in the in vitro enzymatic assay (Forneris et al., 2005).  
 
 
 
 
Figure 1.8. Demethylation of K4H3me2 by LSD1. First, the methylated Lys4 side chain of 
histone substrate is oxidized by the FAD prosthetic group with resultant reduction of oxygene to 
hydrogen peroxide. The resulting imine intermediates is hydrolyzed to generate the demethylated 
H3 tail and formaldehyde (Shi et al., 2004).  
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The presence of other activation markers (e.g. Lys hyperacetylation or Ser 10 
phosphorylation) on H3 greatly decreases catalytic activity of LSD1 (Forneris et al., 
2005). This finding implies that other enzymes, including histone deacetylases, arginine 
demethylases and serin phosphatases must operate before LSD1 activity can occur. 
Therefore, LSD1–mediated H3K4 demethylation seems to be a final epigenetic process 
associated with gene repression (Forneris et al., 2008).  
 
 
1.6.1.   Linking LSD1 to gene repression 
 
LSD1 was originally identified as a component of transcriptional repressor complexes 
comprising transcriptional corepressor protein (CoREST) and HDAC1/2. In association 
with the transcription factor repressor element 1-silencing transcription factor (REST), 
the LSD1-CoREST-HDAC core mediates long-term repression of neuronal genes in non-
neuronal cells and in neuronal precursors. The LSD1-CoREST-HDAC core is 
functionally and structurally conserved (Dallman et al., 2004) and was shown to be also 
involved in various biological processes. In hematopoiesis, the LSD1-CoREST-HDAC 
core associates with growth factor independent 1 transcription repressor (Gfi-1) 
repressing Gfi-1 target genes (Saleque et al., 2007). LSD1-CoREST-HDAC core is also 
involved in silencing mature B-cell genes through direct interaction with the 
transcriptional repressor B lymphocyte-induced maturation protein-1 (Blimp-1) (Su et al., 
2009). The constitutive transrepressor TLX also forms a complex with LSD1-CoREST-
HDAC core, repressing PTEN gene and inhibiting cell proliferation (Yokoyama et al., 
2008).  
LSD1 can also directly interact with p53 to confer p53-mediated transcriptional 
repression, such as the repression of the alpha-fetoprotein (AFP), whereas the well 
known p53 target gene p21 can be actively transcribed without recruitment of LSD1. 
This finding suggests that LSD1 is targeted to chromatin by p53 but likely in a gene-
specific manner (Tsai et al., 2008). Another important indication of LSD1 involvement in 
gene repression is that the DNA methylase regulator DNMT3L recognizes histone H3 
tails that are unmethylated at H3K4 (Ooi et al., 2007). This finding suggests the 
importance of LSD1 in the formation and propagation of heterochromatin through LSD1-
dependent H3K4 demethylation and following de novo DNA methylation.   
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1.6.2.   The role of LSD1 in gene activation 
 
Recent studies implicated LSD1 in transcriptional activation mediated by nuclear 
receptors (the androgen and estrogen receptors, AR and ER) functioning as an H3K9 
demethylase (Garcia-Bassets et al., 2007; Metzger et al., 2005). This function was firstly 
described by Metzger et al. who showed that activation of AR target genes requires 
LSD1-dependent histone H3K9 demethylation. They demonstrated that, following 
hormone treatment, AR and LSD1 colocalize on promoters and stimulate H3K9 
demethylation without altering the H3K4 methylation status and promote ligand 
dependent transcription of AR target genes resulting in enhanced tumor cell growth. 
Consistently, LSD1 knock-down resulted in decreased activation of AR-responsive 
promoters.  
Recently, a genome-wide analysis of LSD1 promoter occupancy following estrogen 
treatment of MCF7 cells has revealed striking results regarding the activatory role of 
LSD1 (Garcia-Bassets et al., 2007). LSD1 occupies nearly 20 % of the total assayed 
promoters and 84 % of these promoters are associated with RNA polymerase II and 
additionally with activation markers such as dimethyl-H3K4 and acetyl-H3K9 suggesting 
that LSD1 is extensively involved in gene activation rather than repression.  
The dual role of LSD1 in gene repression and activation is also demonstrated by the fine 
regulation of growth hormone expression during pituitary development (Wang et al., 
2007). Activation of growth hormone expression is regulated by the transcriptional 
activator pituitary transcription factor 1 (Pit1) during the early phases through recruitment 
of a LSD1-containing mixed lineage leukemia 1 (MLL1) coactivator complex. Pit1 is later 
replaced by zinc finger E-box binding homeobox 1 (ZEB1), a transcriptional repressor 
which recruits a co-repressor complex containing C-terminal binding protein (CtBP), 
CoREST and LSD1, switching off growth hormone expression.  
Until now it is not clear how LSD1 functions as a H3K9 demethylase in association with 
AR, ER or other transcription factors. So far, H3K9 demethylase activity by LSD1 has 
not been detected in in vitro enzymatic assay (Shi et al., 2004; Forneris et al., 2005). 
Possibly, an interacting partner or a post-translational modification of LSD1 could alter 
LSD1 demethylation specificity from H3K4 to H3K9 possibly through allosteric alteration. 
Alternatively and more likely, other H3K9-specific histone demethylases could be 
recruited by LSD1 or by a LSD1-associated protein. In this case, LSD1 might act as a 
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docking or adaptor module for different coactivator complexes that might contain a 
demethylase specific for H3K9. Indeed, it was observed that some chromatin-remodeling 
complexes contain both LSD1 and a H3K9 demethylase of the Jumonji-containing class 
JMJD2C (Wissmann et al., 2007). JMJD2C assembles into the AR complex and 
collaborates AR-target-gene transcription together with LSD1. 
In addition to its transcriptional regulation of individual genes, LSD1 plays an important 
role in interchromosomal interaction and nuclear rearrangement. Hu et al. showed that 
upon treatment of estrogen, LSD1 is recruited to distinct interchromatin granules, long 
thought to serve as “storage” site for the splicing machinery, some transcription 
elongation factors and various chromatin remodeling complexes, enhancing nuclear 
receptor-induced transcription (Hu et al., 2008). 
 
 
1.6.3.   The role of LSD1 in development and differentiation 
 
Since its discovery, the functional role of LSD1 has been actively investigated. LSD1 
appears to be pivotal in development and differentiation. Constitutive knockout of LSD1 
results in mouse embryonic lethality at or before embryonic day 5.5 (Wang et al., 2007; 
Wang et al., 2009). Zygotic LSD1 expression first appeared at the morular stage and 
became ubiquitous in postimplantation embryos. ES cells derived from LSD1 knockdown 
mouse showed severe growth impairment, probably due to increased cell death, 
impaired cell cycle progression, and defects in differentiation. Conditional knockout of 
LSD1 showed defects in pituitary gland development and the Notch signalling pathway 
(Wang et al., 2007). RNAi inhibition of LSD1 in several mammalian haematopoietic 
lineages resulted in impairment of differentiation in vitro (Saleque et al., 2007). In 
addition, LSD1 appears to play conserved roles in meiosis and germ cell development. 
The mammalian LSD1 shows relatively high levels of expression in mouse testes 
(Godmann et al., 2007). Mutations of the fly LSD1 homolg lead to sex-specific embryonic 
lethality and sterility in the surviving (primarily female) offspring, probably owing to 
defects in ovary development (Di Stefano et al., 2007). Mutant in spr-5, the 
Caenorhabditis elegans ortholog of LSD1, exhibited germline immortality by the 
misregulation of spermatogenesis-related genes (Katz et al., 2009). 
    
   
 
Introduction 
 17 
1.6.4.   LSD1 functions beyond histone demethylation 
 
Recent studies have identified non-histone substrates for LSD1 (Huang et al., 2007; 
Wang et al., 2009). LSD1 controls the tumor suppressor activity of p53 by demethylating 
a specific p53 lysine (Lys370) which is required for efficient binding to the transcriptional 
co-activator p53-binding protein-1. Through this interaction, LSD1 blocks p53 pro-
apoptotic activity (Huang et al., 2007).  
Very recently, a DNA methyltransferase was also indentified as a non-histone substrate 
for LSD1 (Wang et al., 2009). Methylation of DNMT1 leads to protein degradation. LSD1 
can directly demethylate and stabilize DNMT1 maintaining global DNA methylation. Thus, 
LSD1 coordinates not only histone methylation but also DNA methylation to regulate 
chromatin structure and gene activity. However, its mode of recognition of a non-histone 
substrate remains unclear, especially in light of the dissimilar amino acid sequences 
surrounding non-histone substrates and H3K4.  
 
 
1.7.   Altered epigenetic modifications in cancer   
 
Given that epigenetic processes are fundamental to the regulation of gene activity, it is 
not surprising that aberrant changes in epigenetic modifications were found in many 
pathological processes (Ozanne et al., 2007; Feinberg et al., 2004; Laird, 2003), 
especially in human tumors (Esteller, 2008; Jones et al., 2007; Widschwendter et al., 
2007).  
Neoplastic transformation also termed as carcinogenesis, is regarded as the multistep 
process whereby cells undergo a change involving uncontrolled cell proliferation, a loss 
of checkpoint control tolerating the accumulation of chromosomal aberrations and 
genomic instability, and mis-regulated differentiation (Lengauer et al., 1998). It is 
commonly thought that silencing of tumor suppressor genes (TSGs) or activation of 
oncogenes through dominant mutation or overexpression of a normal oncogene (proto-
oncogene) initiate carcinogenesis (Hanahan et al., 2000). However, a growing body of 
data has appeared since the mid-1990s indicating that epigenetic alterations may also 
be critical for the evolution of all human cancer types (Jones et al., 2007; Laird et al., 
2003).  
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Global DNA hypomethylation is a widespread phenotype of cancer cells. At the 
individual gene level, DNA hypomethylation can lead to the activation of proto-
oncogenes, the derepression of genes that cause aberrant cell function, or the biallelic 
expression of imprinted genes (also termed loss of imprinting or LOI). On a global 
genomic scale, broad DNA hypomethylation becomes increasingly mutagenic to the 
extent of causing global genomic instability (Allis et al., 2007). Particularly, global DNA 
hypomethylation at regions of constitutive heterochromatin predisposes cell to 
chromosomal translocations and aneuploidy that contribute to cancer progression. 
Another hallmark of cancer is CpGI hypermethylation at TSG promoter regions. 
Abnormal hypermethylation of CpGIs in the 5´ regions of TSGs is integral to their 
transcriptional silencing. Indeed, many TSGs such as RASSFIA (self-sufficiency in 
growth signals), E-cadherin (tissue invasion and metastasis), GST Pi and MLH1 (DNA 
repair capacity) and p19 or RB (limitless replicative potential) were shown to be 
epigenetically silenced in human cancer.  
 
An imbalance of histone modification may also contribute to oncogenic transformation. 
Indeed, changes of histone modification levels were shown to be an indicator of cell 
normality or abnormality. As demonstrated by a study in prostate tumor progression, 
there is a manifest decrease in repressive histone marks and an increase in overall 
acetylation states (Seligson et al., 2005) causing elevated levels of gene transcription 
and genomic instability.  
Mutations, overexpression or malfunction of several histone modifying enzymes such as 
HDACs and HMTs have been shown to be linked to cancer. For example, deregulation 
of a Polycomb group protein (e.g., EZH2) or trithorax group protein (e.g., MLL) HMT acts 
during oncogenic transformation through perturbing a cell’s epigenetic identity, which 
consequently either transcriptionally silences or activates inappropriate genes 
(Schneider et al., 2002; Valk-Lingbeek et al., 2004). In fact, the deregulation of EZH2 or 
MLL has been shown to be associated with increased risk of prostate cancer, breast 
cancer, multiple myeloma, or leukemia (Lund et al., 2004; Valk-Lingbeek et al., 2004). 
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1.8.   Epigenetic therapy of cancer 
 
1.8.1.   DNMT and HDAC inhibitors 
 
Targeting chromatin-modifying effector enzymes has opened up a new horizon for 
cancer therapeutics. There are two main classes of “epi-drugs”: inhibitors of DNMTs and 
HDACs. The nucleoside analogs 5-azacytidine, 5-aza-2´- deoxycytidine and zebularine 
are powerful inhibitors of DNA cytosine methylation (Figure 1.9). These drugs are 
incorporated into the DNA of replicating cells and then interact with all three known 
DNMTs to form covalent intermediates which ultimately inhibit DNA methylation. These 
nucleoside analogs can reactivate silenced genes in tissue culture or in xenograft 
models. Zebularine is being applied for the treatment of certain hematological 
malignancies, particularly myeloid dysplastic syndrome. Despite the lack of specificity of 
nucleoside analogs which inhibit DNA methylation throughout the genome, results from 
clinical trials suggest that demethylation induced by azanucleosides might be of general 
benefit for the reversion of epigenetic lesions in cancer (Wijermans et al., 2008, Mai et 
al., 2009).  
 
 
Clinical trials are also ongoing using inhibitors of various HDACs. Among them, SAHA 
(vorinostat, Zolinza®; Merck) was approved by the US FDA in 2006 for the treatment of 
cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) (Figure 
1.9). The molecular mechanisms mediating the anti-cancer effects of HDAC inhibitors 
are very complex. In part, the antiproliferative effects of vorinostat involve the activation 
of aberrantly repressed TSGs, induction of differentiation and promotion of apoptosis, as 
Vorinostat (SAHA)
Figure 1.9. Chemical structures of epi-drugs 
5-aza-CR      5-aza-CdR       Zebularine Pargyline     Tranylcypromine
DNMT inhibitor HDAC inhibitor LSD1 inhibitor
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well as changes in acetylation levels and function of non-histone proteins (Witt et al., 
2009). 
 
 
1.8.2.   Targeting LSD1 in tumor therapy 
 
Since the discovery of LSD1, there have been increasing efforts to identify or design 
LSD1 inhibitors that could function as antitumor therapeutic agents. Given the frequent 
physical association of LSD1 with HDACs and the positive cooperativity between LSD1 
and HDACs in modifying chromatin, it is very likely that LSD1 and HDACs collaborate to 
repress the transcription of common sets of genes. Thus, chemical inhibitors of LSD1 
may exhibit antitumor activities on their own and/or have synergistic effects with HDAC 
inhibitors (Yang et al., 2007). 
Moreover, LSD1 has been found upregulated in certain high-risk tumors and high levels 
of LSD1 correlated with tumor relapse during therapy (Metzger et al., 2005; Kahl et al., 
2006). At the cellular level, overexpression of LSD1 in prostate carcinoma was sufficient 
to promote AR-dependent transcription in the absence of androgens (Kahl et al., 2006). 
Thus, the development of LSD1 inhibitors may provide an important new therapy of 
cancer.  
LSD1 shares similar folding topology and enzymatic properties with members of the 
flavin-dependant amino oxidas family, including MAOs and PAOs. Owing to the similarity 
between LSD1 and mono-amineoxidases (MAOs)/poly-amineoxidases (PAOs), both 
MAO inhibitors and polyamine analogues have been shown to inhibit LSD1 enzymatic 
activity (Lee et al., 2006; Huang et al., 2007). Pargyline or tranylcypromine which are 
well-known MAO inhibitors and used clinically as antidepressant, have been proved to 
be LSD1 inhibitors (Figure 1.9). Pargyline blocks demethylation by LSD1 and 
consequently blocks androgen-receptor-dependent transcription, suggesting that 
modulation of LSD1 activity offers a new strategy to regulate androgen receptor 
functions which are important in prostate cancer (Metzger et al., 2005). Biguanide and 
bisguanidine polyamine analogues have been described to inhibit LSD1 and be capable 
of reactivating genes that are pathologically silenced in the development of colon cancer 
including members of the secreted frizzle-related proteins (SFRPs) and the GATA family 
of transcription factor (Huang et al., 2007). Despite the fact that MAO inhibitors and 
polyamine analogues may serve as a valuable starting point for the design of more 
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potent LSD1 inhibitors, they have limitations for the clinical use due to their action on 
MAOs and PAOs and anticipated side effects, and no data is yet available about their 
effects in cancer.  
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2.   Aims of this work 
 
 
LSD1 has been found to be upregulated in high-risk prostate cancer and overexpression 
of LSD1 was shown to be correlated with tumor relapse. Aberrant overexpression of 
LSD1 does not seem to be restricted to prostate cancer but rather represents a general 
phenomenon of most aggressive cancer types. The goals of my study are to analyze the 
functional role of LSD1 in neuroblastoma and breast cancer and to evaluate its use as a 
predictive marker for aggressive tumor biology. For the determination of LSD1 protein 
levels in tissue specimen, an ELISA for LSD1 has to be developed. Using either RNA 
interference method or small molecule inhibitor for LSD1 in a cell culture system, we 
wanted to analyze the functional role of LSD1 in proliferation and transcriptional 
regulation. Furthermore, we wanted to provide evidence that LSD1 could be targeted in 
cancer therapy. For this purpose, the effect of MAOIs on the tumor growth in a xenograft 
mouse model was investigated. To find specific LSD1 inhibitors, a high-throughput 
screening assay was developed and employed to screen a compound library for novel 
small molecule inhibitors of LSD1. 
Results 1: LSD1 in neuroblastoma  
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3.   LSD1 in neuroblastoma 
 
 
3.1.   Neuroblastoma 
 
Neuroblastoma is the most common extracranial tumor of childhood. This tumor 
originates from precursor cells of the peripheral sympathetic nervous system and usually 
arises in a paraspinal location in the abdomen or chest. Neuroblastoma accounts for 7-
10 % of all childhood cancers and is the most common cancer diagnosed during infancy 
(Brodeur et al., 2003). 
The clinical course of neuroblastoma is very heterogeneous. While neuroblastoma (NB) 
with favourable biology as well as the benign variants ganglioneuroblastoma (GNB) and 
ganglioneuroma (GN) spontaneously regress or differentiate without any therapeutic 
intervention, neuroblastoma with unfavourable biology often fatally progresses 
regardless of multimodal therapy (Brodeur et al., 2003; Maris et al., 2007). More than 
60 % of neuroblastomas remain with their poor prognosis despite the application of 
aggressive multimodal therapies including surgery, radiation therapy, and cytotoxic 
chemotherapy. The survival rate for the MYCN-amplificated neuroblastoma with tumor 
stage 4 is less than 20 %. Unfortunately, new biologically based therapeutic options 
such as induction of differentiation using retinoic acid derivatives (Sidell et al., 1983), 
blockage of the tyrosine receptor kinase pathway or inhibition of angiogenesis have 
shown less significant survival advantage. Therefore, the identification of novel drug 
targets and development of new therapeutic options are urgently needed. 
 
High-throughput analysis including expression profiling (Schramm et al., 2007; Schulte 
et al., 2008) and array CGH (Schleiermacher et al., 2007; Chen et al., 2006; 
Vandesompele et al., 2005) have identified several patterns in heterogenous 
neuroblastomas. Based on the patterns of genetic change, neuroblastomas can be 
classified into three subtypes that are predictive of clinical behaviour. The first favourable 
tumor group is characterized by near-triploid karyotypes with whole chromosome gains. 
These tumors rarely have structural rearrangements and usually express the TrkA 
neurotrophin receptor. The second tumor group comprises the near-diploid or tetraploid 
tumors with low TrkA expression and structural chromosomal aberration. The third 
unfavourable tumor group comprises highly aggressive and rapidly progressing tumors 
Results 1: LSD1 in neuroblastoma  
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with high TrkB expression, MYCN amplification and aberrant diploid chromosome with 
1p36 and 11q deletion (Attiyeh et al., 2005). 
MYCN amplification was shown to be predominantly associated with rapid tumor 
progression and a poor outcome, serving as a powerful predictor of a poor prognosis. 
MYC oncoproteins are transcription factors that can lead to deregulated growth 
proliferation by activating genes related to cell cycle progression. MYCN amplification 
was detected in 25 % of all neuroblastomas. Brodeur et al. revealed that the 3 year 
event-free survival (EFS) of infants whose tumors lacked MYCN amplification was 93 %, 
whereas those with tumors that had MYCN amplification had only a 10 % EFS (Brodeur 
et al., 2003). However, pharmacological intervention to modulate central oncogens like 
MYCN has not yet been achieved. Many of the genes discriminating between favourable 
and unfavourable neuroblastomas belong to the functional category of transcription 
factors which are very difficult drug targets. 
 
A relatively new therapeutic approach is targeting epigenetic enzymes which are 
involved in tumor progression and modulate broad expression patterns. Indeed, histone 
acetylation and DNA methylation have been shown to specifically regulate central genes 
in aggressive neuroblastoma (de Ruijter et al., 2004; Stupack et al., 2006; Jones et al., 
2001). Treatment with histone deacetylase (HDAC) inhibitors and DNA-demethylating 
agents has proven effective against neuroblastoma cells in vitro (de Ruijter et al., 2004), 
and are currently being evaluated for treating neuroblastoma in vivo.  
 
In a previous study, our group has shown that LSD1 is involved in malignant progression 
of prostate cancer and controls androgen receptor-dependent transcription in the 
absence of androgen. In this study, we wanted to analyze the implication of LSD1 in 
neuroblastoma. 
Results 1: LSD1 in neuroblastoma  
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3.2.   Results 
 
This work was carried out in collaboration with Dr. Jutta Kirfel (Bonn), Johannes Schulte 
(Essen), Prof. Angelika Eggert (Essen), Ludger Klein-Hitpass (Essen) and Rogier 
Versteeg (The Netherlands).  
 
 
3.2.1.   LSD1 is strongly expressed in poorly differentiated neuroblastomas 
 
We analyzed LSD1 expression in primary neuroblastic tumors including malignant 
neuroblastomas, benign ganglioneuroblastomas and ganglioneuromas. A tissue 
microarray was prepared for this purpose incorporating 99 primary, untreated tumors, of 
which 77 were neuroblastomas and 22 were ganglioneuroblastomas and 
ganglioneuromas. LSD1 expression was significantly higher in poorly differentiated than 
in differentiated neuroblastomas (Mann-Whitney-Test, P = 2.6x10-5, Figure 3.1B). LSD1 
expression was also higher in differentiated neuroblastomas than in ganglioneuromas 
and ganglioneuroblastomas (Mann-Whitney-Test, P = 8.2x10-5, Figure 3.1B). LSD1 was 
not expressed in non-malignant cells, such as stromal tissue or infiltrating leukocytes 
(Figure 3.1A). Similar results were obtained in an independent cohort of 110 neuroblastic 
tumors previously analyzed on Affymetrix microarrays when these data were reanalyzed 
for LSD1 mRNA levels (Figure 3.1C). Kaplan-Meier analysis revealed that a low LSD1 
mRNA expression level was predictive of event-free survival (EFS) in the latter cohort 
(log rank-test, p=0.021, Figure 3.1D). In contrast to mRNA expression, LSD1 protein 
expression which was measured semi-quantitatively on the TMA using 
immunohistochemistry failed to serve as a statistically significant predictive parameter of 
survival and relapse or progression. The amplification of the MYCN oncogene, a known 
marker for unfavourable neuroblastoma did not correlate with LSD1 expression (data not 
shown). 
Results 1: LSD1 in neuroblastoma  
 
26 
 
 
 
 
 
Figure 3.1. LSD1 is strongly expressed in poorly differentiated neuroblastoma. (A) 
Immunohistochemical staining of LSD1 in neuroblastic tumors. In poorly differentiated 
neuroblastomas (I and II), nuclear LSD1 staining is observed in almost all tumor cells. In contrast, 
in benign ganglioneuroblastomas (III)/ganglioneuroma (IV), LSD1 staining is mild or absent. The 
few signals marked by arrows in III and IV represent nucleoli of differentiated ganglia. Infiltrating 
leukocytes (L) in II, and Schwannian stroma do not display any immunoreactivity for LSD1 (III/IV). 
(B) A tissue microarray with 99 primary neuroblastic tumors was used to analyze LSD1 expression 
in neuroblastoma and its benign derivates. Expression was significantly higher in poorly 
differentiated neuroblastomas (NB pd) than in differentiated neuroblastomas (NB diff) or 
ganglioneuroblastomas/ganglioneuromas (GNB/GN). (C) LSD1 mRNA expression in an 
independant cohort of 110 neuroblastic tumors analyzed with Affymetrix microarrays. (D) Kaplan-
Meier analysis of 110 neuroblastic tumors shows that low LSD1 mRNA expression levels are 
predictive of EFS. 
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3.2.2.   LSD1 expression in neuroblastoma cell lines 
 
LSD1 protein expression in neuroblastoma cell lines was assessed by Western blotting. 
All cell lines strongly expressed LSD1 (Figure 3.2A). As all existing neuroblastoma cell 
lines were established from undifferentiated, aggressive tumors, this result was 
consistent with our data from primary tumors where aggressive tumors showed high 
LSD1 expression. We then asked if induction of differentiation might result in down-
regulation of LSD1. We therefore treated SY5Y and BE2C neuroblastoma cells with all-
trans retinoic acid (RA), a drug known to induce differentiation of neuroblastoma cells 
(Cuende et al., 2008). After 12 days, RA treatment resulted in morphological changes 
such as neurite development and reduced proliferation (Figure 3.2B). Upon 
differentiation, a significant down-regulation of LSD1 was detected (Figure 3.2C) 
 
 
Figure 3.2.  (A) LSD1 protein expression in 
different neuroblastoma cell lines. β-actin was 
used as the loading control. (B) Treatment of SH-
SY5Y cells with all-trans retinoic acid (RA) 
resulted in a significant increase in the number 
and length of neurites, which served as an 
indicator of differentiated phenotype. (C) After 12 
d, retinoic acid treatment induced differentiation of 
SH-SY5Y and BE(2)-C neuroblastoma cells. 
LSD1 protein levels were significantly reduced in 
both cell lines. β-actin served as the loading 
control. 
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3.2.3.   Silencing of LSD1 impairs neuroblastoma growth and induces cellular 
differentiation in vitro 
 
To further analyze the functional relevance of LSD1 in neuroblastic tumors, SH-SY5Y 
cells were transiently transfected with siRNA directed against LSD1 or with a scrambled 
control siRNA. A significant LSD1 knock-down was detected on protein levels after 
transfection with either 10 or 20 pmol of siRNA (Figure 3.3A).  
Upon siRNA-induced knock-down of LSD1, a significant decrease in cell viability was 
detected in MTT assays (Figure 3.3B). Decreased viability was accompanied by the 
appearance of morphological features indicating differentiation, such as outgrowth of 
neurite-like structures (Figure 3.3C). 
 
 
Figure 3.3. (A) Transfection of SH-SY5Y neuroblastoma cells with LSD1-directed siRNA resulted 
in reproducible knockdown of LSD1 protein levels. β-actin served as the loading control. (B) MTT 
assay of SH-SY5Y treated with siRNA against LSD1 detected a significant reduction in cell number 
after 72 h incubation. (C) Phase-contrast microscopy of SH-SY5Y cells transfected either with 
siRNA against LSD1 or scrambled control siRNA. Phenotypic changes were observed 72 h 
posttreatment.  
A 
B 
C 
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Microarray analysis revealed changes in expression that were consistent with these 
observations 72 hours after LSD1 knock-down (Figure 3.4). At this time, 28 genes were 
significantly induced at least 1.5-fold and 29 genes were significantly repressed at least 
1.5-fold. Among the 28 induced genes, 4 genes such as TNS1, TPM1, DNM2 and 
DNAL4 are known to be related to cytoskeletal remodeling and neurite dynamics 
(Schevzov et al., 2005; Dehmelt et al., 2006; Okamoto et al., 2001). TNS1 encodes 
tensin1 which localizes to focal adhesions, attaching cells to the extracellular matrix. 
Tropomyosin1 (TPM1) is an integral component of actin microfilaments and is recruited 
to the sprouting neurite. Dynein4 (DNAL4) also 
contributes to the generation of new neurites by 
pushing the microtubule bundles outward. DNM2 
encodes dynamin2 which is expressed in 
synaptosomes and controls synaptic vesicle 
recycling. Upregulation of TNS1, TPM1 DNM2 
and DNAL4 indicates the differentiation of 
neuroblastoma cells upon knock-down of LSD1.  
 
 
Figure 3.4.  Microarray analysis of SH-SY5Y cells treated 
with siRNA directed against LSD1 or with scrambled control 
siRNA revealed an induction of genes involved in 
differentiation and neurite dynamics (red arrow). siRNA-
mediated knockdown of LSD1/AOF2 resulted in reduction of 
LSD1 mRNA as expected (blue arrow).  
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To confirm the expression change detected via microarray analysis, TaqMan quantitative 
RT-PCR was performed using LSD1/AOF2, TNS1, TPM1, DNM2 and DNAL4 primers 
(Figure 3.5). Upon knock-down of LSD1, the LSD1 mRNA level decreased, while the 
identified 4 genes increased about 1.5-fold as shown in the microarray analysis.  
 
 
 
 
Figure 3.5. TaqMan quantitative RT-PCR confirmed the expression changes detected via microarray 
analysis for LSD1, DNAL4, DNM2, TNS1 and TPM1. * p < 0.1,** p < 0.5 
 
 
3.2.4.   Knock-down of LSD1 upregulates putative tumor suppressor genes and 
alters gene specific H3K4 methylation  
 
To determine whether LSD1 knock down influences the gene-specific methylation status 
regulating directly gene expression, TFPI2 and XRCC5 genes were chosen which were 
also induced upon knock-down of LSD1. The TFPI2 gene encodes the protein, tissue 
factor pathway inhibitor 2 which is a putative tumor suppressor gene. Epigenetic 
silencing of TFPI2 was observed in hepatocellular carcinoma, malignant melanoma and 
invasive breast cancer cells (Wong et al., 2007;, Nobeyama et al., 2007), while ectopic 
expression of TFPI2 suppresses the proliferation and invasiveness of hepatocellular 
Results 1: LSD1 in neuroblastoma  
 
31 
 
carcinoma cells, suggesting its role in inhibition of the growth of neoplasm (Wojtukiewicz 
et al., 2003). XRCC5 encodes the Ku80 protein which functions in nonhomologous DNA 
end joining and is involved in the double-strand break repair pathway by interacting with 
BRCA1 (Wei et al., 2008). Epigenetic inactivation of XRCC5 in cancers such as non-
small cell lung cancer was also reported (Lee et al., 2007).  
 
 
 
Figure 3.6. SHEP and LAN1 cells were transfected with LSD1-directed siRNA. ChIP (left) was 
performed with the indicated antibodies. The precipitated DNA was amplified by PCR using primers 
flanking the TFPl2 proximal locus or XRCC5 proximal locus. siRNA mediated knockdown of LSD1 
was verified by quantitative PCR analysis (right). 
 
 
For this study, SHEP and LAN1 cells were treated with siRNA directed against LSD1 or 
with a scrambled control siRNA and were subjected to TaqMan quantitative RT-PCR to 
confirm the induction of TFPI2 and XRCC5 as observed in the microarray. In both cell 
lines, TFPI2 was 17-fold and XRCC5 was 1.5-2 fold induced upon knock down of LSD1. 
To assess whether TFPI2 and XRCC5 are direct targets of LSD1, cells were subjected 
to chromatin immunoprecipitaiton (ChIP) using α-LSD1 and α-diMeK4H3 antibodies. 
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ChIP analysis revealed that LSD1 is present at the -300 proximal promoter regions of 
the TFPI2 and XRCC5 (Figure 3.6, right panel). Silencing of LSD1 decreased the 
occupancy of LSD1 on the proximal promoter regions. This was accompanied by 
significant increase in di-methylation on H3K4 which is consistent with up-regulation of 
TFPI2 and XRCC5. These findings suggest that LSD1 regulates directly the transcription 
of TFPI2 and XRCC5 through demethylation of H3K4. Furthermore, knock down of 
LSD1 can reactivate the tumor suppressor gene TFPI2 and the DNA repair gene XRCC5 
which are often epigenetically silenced in malignant tumors. 
 
 
3.2.5.   LSD1 inhibition using MAOIs impairs neuroblastoma growth in vitro  
 
Figure 3.7. (A) Treatment of SHEP (red), SH-SY5Y (green), or LAN-1 (blue) neuroblastoma cells 
with pargyline, tranylcypromine, or clorgyline resulted in extensive reduction of cell numbers and 
MTT uptake. (B) Western blot analysis confirmed an accumulation of H3K4 dimethylation upon 
treatment with MAOIs. In contrast, LSD1 protein levels were not affected. β-actin served as the 
loading control. 
 
A
B
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We also analyzed the effect of LSD1 inhibition on cell viability and methylation levels. 
The catalytic domain of LSD1 has a high sequence homology to monoaminoxidase 
(MAO), and they share a common demethylating mechanism. Importantly, MAO 
inhibitors (MAOI) were shown to inhibit LSD1 activity (Lee et al., 2006). Treatment of 
neuroblastoma cell lines with the reversible MAOI, pargyline and clorgyline, or with the 
irreversible MAOI, tranylcypromine, impaired growth of neuroblastoma cells in a dose-
dependent manner (Figure 3.7A). Reduced viability was accompanied by the increase of 
global di-methylation of lysine 4 in histone 3 (diMeH3K4) (Figure 3.8B).  
 
 
3.2.6.   Small molecule inhibitor of LSD1 inhibits xenograft tumor growth  
 
A xenograft mouse model was used to assess the potential therapeutic value of small 
molecule inhibitors targeting LSD1 against neuroblastic tumors in vivo. 24 nude mice 
(nu/nu) were subcutaneously injected with 2.0x107 of SH-SY5Y neuroblastoma cells in 
the flank. Tranylcypromine treatment by intraperitoneal injection of 2 mg tranylcypromine 
once daily was started at the time of xenograft injection, and sodium chloride was 
injected into control animals. During treatment, one mouse died of peritonitis and six 
mice died from tranylcypromine-induced seizures. 17 surviving mice were sacrificed 21 
days after the injection of tumor cells. Xenograft tumors in the mice treated with 
tranylcypromine were significantly smaller than the control. (T-test, p= 0.044, Figure 8A). 
Histological examination revealed that the tranylcypromine treatment resulted in a higher 
content of fibrosis and extensive necrosis in the xenograft (Figure 3.8B). 
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Figure 3.8.  (A) Relative tumor weight of SH-SY5Y xenografts in nude mice treated with 2 mg 
tranylcypromine (MAOI) or control (NaCl). Mice were sacrificed, and the tumors were weighed 21 d 
after s.c. tumor cell inoculation. Tumors in mice receiving tranylcypromine were significantly smaller 
than mice receiving saline only. (B) histologic appearance of tumors treated without MAOI (saline, 
I) or with 2 mg tranylcypromine (II) for 21 days. Sections were stained with H&E. Note the massive 
necrosis and hemorrhage of tumors in the MAOI-treated xenografts (II). 
 
A B 
Results 2: LSD1 in breast cancer 
 
 35 
4.   LSD1 in breast cancer 
 
 
4.1.   Breast cancer 
 
In the industrialized countries of the Western world breast cancer is the most common 
tumor in women, and along with lung cancer the most important cause of cancer-
associated morbidity and mortality.  
Breast cancer is a heterogeneous disease that has distinct histopathological features, 
genetic and genomic variability and diverse prognostic outcomes. In premalignant 
stages, atypical ductal hyperplasia (ADH) arises in the breast terminal ductal lobular unit 
(TDLU) and develops to ductal carcinoma in situ (DCIS). DCIS may enter malignant 
stages and give rise to invasive breast cancer (IBC). Once cells have invaded, the risk 
for developing metastasis significantly increases. During this multistage process, control 
of proliferation, survival, differentiation and migration become deregulated. The 
complexity and heterogeneity of breast cancer make it harder to identify novel therapies 
and to improve existing therapies for the treatment and prevention of this disease 
(Vargo-Gogola et al., 2007). 
 
Currently, breast cancer patients are managed based on a constellation of clinical and 
histopathological parameters in conjunction with assessment of hormone receptor 
(estrogen (ER) and progesterone receptor (PR)) status and Her2 (human epithelial 
receptor 2, also known as HER-2/neu or erB-2) expression and gene amplification.  
ER expression is observed in 40-70 % of breast cancers which has a more favourable 
prognosis than ER-negative breast cancers (Corinne et al., 2007). With ER positive 
breast cancer, homone-blocking medications, such as tamoxifen, slow the cancer’s 
growth.  
About 20 % of invasive breast cancer belong to the Her2-positive group which can 
spread aggressively and has a poor prognostic outcome. Trastuzumab (Herceptin) is a 
monoclonal antibody targeted to the Her2 protein that can be used for this type of breast 
cancer. However, response rate of 35 % to the Her2-targeted drugs seems to be a 
limiting factor for the treatment of the Her2-postive breast cancer (Osborne et al., 2004). 
Breast cancers that are Her2-negative and also lack receptors for estrogen and 
progesterone are referred to as “triple negative” and comprise approximately 20 % of all 
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invasive breast cancers. This form of the disease is highly aggressive with the worst 
prognostic outcome. Aggressive chemotherapy is the only modality of systemic therapy 
for the triple negative subtype. Therefore, the identification of novel drug targets and 
development of new therapeutic options are urgently needed for the treatment of ER-
negative breast cancers with resistance to the Her2 blockers or hormone therapy.   
 
Considering the recent evidence that LSD1 critically controls hormone-dependent gene 
expression, cellular growth and malignant progression of prostate cancers, we 
investigated for the first time the role of LSD1 in breast cancer.  
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4.2.   Results 
 
4.2.1.   Development of LSD1 ELISA 
 
To analyze the LSD1 expression level in breast tumor, both fresh-frozen and formalin-fixed, 
paraffin-embedded tissue specimens of ductal and lobular breast cancer were used for this 
study. Initial immunohistochemical staining of paraffin-embedded tissue specimens revealed 
moderate nuclear expression in luminal cells of normal breast glands and ER-positive cancers 
(histological grade 2). Significantly more intense staining was observed in ER-negative breast 
cancers (histological grade 3), in which every tumor cell showed a strong and specific nuclear 
staining pattern (Figure 4.1). 
 
 
Figure 4.1. Overexpression of LSD1 in breast tumor. Immunohistochemical staining of LSD1 was shown 
in normal breast tissue and breast cancer (histologic grade G2 and G3). 
 
 
I aimed to measure LSD1 expression levels in breast tumors using an LSD1 ELISA 
assay. Since no commercial ELISA for LSD1 was available, LSD1 ELISA was developed 
(Figure 4.2). 96-well Maxisorb microplates were incubated with tissue protein lysates (40 
µg) in coating buffer (50 mM sodium carbonate buffer, pH 9.2) overnight at 4 °C. After 
removal of the coating solution, the wells were blocked with 200 µl blocking buffer 
(Roche) for 1 h at room temperature. After rinsing with washing buffer, the wells were 
incubated with α-LSD1 antibody in 100 µl blocking buffer for 1 h at 25 °C followed by 
three washing steps with 200 µl PBS-T. After addition of 100 µl HRP-labelled α-mouse, 
the wells were incubated for 0.5 h and washed three times. Finally, 100 µl of the TMB 
Breast cancer (grade 3)Normal breast
Anti-LSD1
Breast cancer (grade 2)
500 µm 500 µm 100 µm
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substrate solution were added to each well. The conversion of substrate was stopped by 
addition of 100 µl of 2 N sulphuric acid solution. The optical density was determined in 
an ELISA reader at 450 nm. The N-terminal his6-tagged LSD1 ∆N (166-852) protein 
 
 
Figure 4.2. Development of LSD1 ELISA. Maxi-sorb microplates were incubated with a series of 
dilution of recombinant his6-tagged LSD1 ∆N (166-852) protein (1.0, 3.1, 9.3, 27.8, 83.3 and 250.0 
µg/L) and breast tumor tissue protein lysate (3, 10, 30 and 60 µg/well) in coating buffer (50 mM 
sodium carbonate buffer, pH 9.2) overnight at 4 °C.  Antibody dilution ratio was modified for the 
recombinant LSD1. (α-LSD1, 1:4000; HRP-labelled α–mouse, 1:1000). Otherwise, all steps were 
performed as described above.  
 
 
 
Figure 4.3. (A) Dose-response curve of LSD1 ELISA. A serial dilution of the purified his6-tagged 
LSD1 ∆N (166-852) ranging from 1 to 250 µg/L was used as a calibrator in the LSD1 ELISA to 
generate the dose-response curve.  Linear range was 27.8 -250.0 µg/L and the linear correlation 
coefficient (R2) was 0.99.  The detection limit was estimated as the minimum analyte concentration 
evoking a response significantly different from that of the zero calibrator. The detection limit of the 
assay was 27.8 µg/L (P < 0.01).  (B) Linearity of dilution curves for breast tumor lysates. A 
series dilution of breast tumor tissue protein lysates was used in the linearity study.  In the range of 
3 – 60 µg protein lysates, the dilution curve was close to linear (R2=0.99). 
 
Anti-mouse HRP-conjugated
TMB substrate
Anti-LSD1, mouse monoclonal IgG
LSD1 LSD1
LSD1 LSD1 protein
Blocking reagent
Other proteins
B
0.000
0.200
0.400
0.600
0.800
1.000
1.200
1.400
1.600
0 10 20 30 40 50 60 70
Tumor tissue lysates (µg)
Serial dilution of breast tumor tissue lysates
A
b
s
o
rb
a
n
c
e
A
b
s
o
rb
a
n
c
e
A
0.000
0.500
1.000
1.500
2.000
2.500
0 50 100 150 200 250 300
Recombinant LSD1 (µg/L)
0.10
0.15
0.20
0.25
0.30
0 10 20 30
(µg/L)
Standard curve of recombinant LSD1
A
b
s
o
rb
a
n
c
e
*
*
A
b
s
o
rb
a
n
c
e
Results 2: LSD1 in breast cancer 
 
 39 
The assay was validated by recombinant LSD1 protein and performed in a quantitative 
manner over a broad spectrum of LSD1 protein concentrations between 1 to 250 µg/L 
and also after serial dilution of protein lysates from breast cancer tissue specimens 
(Figure 4.3). Linear range of recombinant LSD1 protein was 27.8 – 250.0 µg/L, while 
tumor tissue protein lysate showed linearity in the range of 3 - 60 µg. For the following 
ELISA assay, 40 µg protein lysates was used pro well. 
 
 
4.2.2.   LSD1 is strongly expressed in ER-negative breast cancer 
 
The established ELISA was used to analyze several breast cancer specimens. 
 
 
 
Figure 4.4. Overexpression of LSD1 in ER-negative breast tumor. (A) LSD1 expression level in 26 
ER positive and 37 ER negative breast tumor was analyzed with ELISA for LSD1. ER (+), ER-positive; 
ER (-), ER-negative. (B) LSD1 expression in normal and tumor tissue extracts was determined by 
western blot. Coomasie staining was used as the loading control. N, normal breast tissue; T, breast 
tumor tissue. (C) Statistcal significance test of ELISA was done by two-sided, non-parametrical Mann-
Whitney U-test to analyze differences in expression levels among normal, ER-positive and ER-negative 
groups. LSD1 expression was significantly higher in ER-negative breast tumor than in ER-positive 
tumor or normal tissue (P < 0.001).  
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In protein lysates of snap-frozen primary breast tissues including 20 normal breast 
tissues, 26 ER-positive and 37 ER-negative breast tumors, LSD1 protein was 
significantly stronger expressed in ER-negative breast cancers than in ER-positive 
cancers or normal tissue (Mann-Whitney-U-test, P < 0.001, Figure 4.4A and 4.4C). 
There was a trend of slightly higher expression comparing ER-positive breast cancer and 
normal breast tissue, but this did not reach statistical significance. Similar results were 
seen in a small set of breast cancer specimens analyzed by Western blot analysis. LSD1 
was stronger expressed in ER-negative breast tumors compared to normal breast 
tissues and ER positive tumors (Figure 4.4B).  
 
 
aLSD1 low, 0 ≤ score ≤ 9; LSD1 high, 9 < score ≤ 12
bFisher`s exact test (two sided).
cER neg, score = 0; ER pos, score =12
dPR low, 0 ≤ score ≤ 6; high, 6 < score ≤ 12; 
PR, progesterone receptor
eHer2/erbB2, low, score 0 or 1; high, score 2 or 3
Table 4.1. Correlation between histopathological data and 
LSD1 expression in tumor specimens from 38 breast cancer 
patients
Her2/erbB2e
Low                   14 (88)              16 (73)              0.426
High                    2 (12)                6 (27)
PR statusd
Low                   7 (44)                 21 (95)            0.001
High            9 (56)                   1 (5)
ER statusc
Neg                   3 (19)                 20 (91)            < 0.001
Pos                  13 (81)                   2 (9)            
Nodal status
Neg                  12 (75)                14 (64)             0.504
Pos                4 (25)                  8 (36)
Size
pT1                    7 (44)                 11 (50)           0.752
PT2-4                9 (56)            11 (50)           
LSD1 lowa, n (%)        LSD1 higha, n (%)
(n = 16)                      (n = 22)                 P b
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Significant inverse correlation between LSD1 expression and ER status was also seen in 
detailed immunohistochemical analysis. To statistically calculate the association 
between histopathological parameters and LSD1 expression levels (Table 4.1), tumor 
specimens were classified into a group with low LSD1 expression (n=16) and a second 
group with high LSD1 expression (n=22). Results in table 4.1 clearly indicated that 
strong nuclear LSD1 staining (score > 9) was associated with negative ER status (score 
= 0) (Fisher´s exact test, P < 0.001, Table 4.1). Consistently high LSD1 expression also 
correlated with low PR expression (score ≤ 6) (P = 0.001). Neither tumor size and nodal 
status nor Her2/erbB2 status showed any correlation with LSD1 expression.  
Considering that hormone receptor expression in breast cancer is associated with a 
significantly better prognosis (Cui et al., 2005), high LSD1 expression appears to provide 
a biomarker for aggressive tumor biology associated with hormone receptor-negative 
breast cancer. 
 
 
4.2.3.   LSD1 inhibition using MAOIs confers growth inhibition and increase of 
global H3K4 methylation in vitro 
 
The catalytic domains of LSD1 and monoaminoxidases (MAOs) share structural 
homology and make use of the same catalytic mechanism (Lee et al., 2006). Therefore, 
we used the MAO inhibitors tranylcypromine and clorgyline to inhibit LSD1 in breast 
cancer cell lines in vitro.  Four different breast cancer cell lines, all of which strongly 
expressed LSD1 (Figure 4.5B) were tested. Treatment with tranylcypromine and 
clorgyline for 72 hours impaired cell growth in a dose-dependent manner (Figure 4.5A) in 
all four cell lines. In contrast to our clinical data in vivo, LSD1 expression levels or 
sensitivity to MAOIs did not differ between ER-positive and ER-negative cell lines in vitro. 
To address whether reduced cell viability after treatment with MAOIs correlates with 
LSD1 inhibition, we analyzed the methylation status of lysine 4 in histone 3 in cells 
before and after treatment. Upon treatment of MAOIs, global di-methylation of lysine 4 in 
histone H3 increased, while LSD1 enzyme levels were not altered (Figure 4.5B). 
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Figure 4.5.  Reduction in cell growth and increase of global H3K4 methylation upon MAOIs 
treatment. (A) Four different breast cancer cells were treated with Tranylcypromine and 
Clorgyline for 72 h for MTT assay. MAOIs treatment resulted in extensive reduction of cell 
numbers. (B) Western blot analysis confirmed an accumulation of H3K4 di-methylation upon 
treatment with tranylcypromine and clorgyline for 24 h. LSD1 protein levels were not affected. β-
actin served as the loading control. 
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4.2.4.   siRNA-mediated knock down of LSD1 reduces cellular growth 
 
To analyze the consequences of reduced LSD1 expression, MDA-MB 453 and MDA-MB 
231 cells were transiently transfected with 15 nM siRNA directed against LSD1 or with 
15 nM scrambled control siRNA. Significant LSD1 knock-down was detected by 
measuring protein levels 3 days after transfection by Western blot (Figure 4.6B). MTT 
assays indicated that the silencing of LSD1 caused a significant decrease in cell growth 
and viability (Figure 4.6A). Similar effects were also seen in MCF7 and T47D cells. 
Morphologically no sign of apoptosis was detected, but the LSD1 inhibition appeared to 
affect the number of dividing cells consistent with a previous report that knock-down of 
LSD1 leads to G2/M cell cycle arrest (Scoumanne et al., 2007). 
 
 
Figure 4.6.  Decreased cellular growth upon siRNA mediated knock down of LSD1. (A) A 
significant reduction in cell number was observed in MTT assay upon knock-down of LSD1. MDA-
MB 231 and MDA-MB 453 cells were treated with siRNA against LSD1 for 12 days. (B) Knock-
down of LSD1 protein levels was determined 6 days after transfection by western blot. β-actin 
served as the loading control.  
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4.2.5.   Knock-down of LSD1 induces downregulation of proliferation associated 
genes and alters target gene-specific H3K9 methylation 
 
Considering that LSD1 regulates gene-expression through modification of histone 
methlyation in gene promoter regions and previous evidence that silencing of LSD1 
decreased cellular proliferation, we further analyzed expression of proliferation related 
genes by quantitative RT-PCR (qRT-PCR). As illustrated in figure 4.7A CCNA2 and 
ERBB2 were downregulated after LSD1 knock-down both in ER-positive MCF7 or ER-
negative MDA-MB 231 and MDA-MB 453 cells (66 - 83% decrease in ERBB2 mRNA 
level; 40 – 65 % decrease in CCNA2 mRNA level). Down-regulation of the Her2/erbB2 
protein level was confirmed 6 days after knock-down of LSD1 in MDA-MB 231 cells 
(Figure 4.7B). However, in MDA-MB 453 and MCF7 cells, Her2/erbB2 protein was highly 
expressed and we could not detect any significant change in Her2/erbB2 protein level 
upon knock-down of LSD1. Possibly the transient changes in RNA levels by the 
transfected siRNA were not robust enough in these cell lines to cause significant and 
persistent changes in protein levels. 
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Figure 4.7. Down-regulation of CCNA2 and ERBB2 mRNA expression and enrichment of H3K9 di-
methylation in the promoter region upon knock down of LSD1. (A) Quantitative PCR analysis was done 
in 3 different breast cancer cells treated with siRNA directed against LSD1 or with scrambled control siRNA. 
CCNA2 and ERBB2 mRNA expressions were down-regulated 3 days after knock-down of LSD1. 18S rRNA 
was used as the endogenous reference gene. (B) Reduction in Her2/erbB2 protein expression 6 days after 
knock down of LSD1 was determined by western blotting. (C) Enrichment of H3K9 di-methylation in the 
proximal promoter region of CCNA2 or ERBB2 was observed upon knock down LSD1 using ChIP assay. 
The sonificated chromatin of MCF7 cells was immunoprecipitated with α-LSD1, α-K9H3me2 and α-
K4H3me2. The precipitated DNA was amplified by PCR using primers flanking the CCNA2 proximal locus or 
ERBB2 proximal locus. *P < 0.05. 
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To asses whether the promoters of CCNA2 and ERBB2 are direct or rather indirect 
targets of histone  modification by LSD1, MCF7 cells treated with siRNA directed against 
LSD1 or with a scrambled control siRNA were subjected to chromatin 
immunoprecipitation (ChIP) using α-LSD1, α-K9H3me2 and α-K4H3me2 antibodies. 
ChIP analysis indeed confirmed that LSD1 is present at the proximal promoter of the 
CCNA2 and ERBB2 gene. Knock down of LSD1 decreased the occupancy of LSD1 on 
CCNA2 (from -137 to -30) and ERBB2 (from -309 to -220) promoter regions (Figure 
4.7C). This was accompanied by significant increase in dimethylation on H3K9 which 
has been previously shown to result in transcriptional repression. In contrast, after LSD1 
knock-down, genomic DNA corresponding CCNA2 and ERBB2 proximal locus were not 
enriched with α-H3K4me2 antibody. This finding is consistent with results observed 
above for down-regulation of ERBB2 and CCNA2 upon knock down of LSD1, suggesting 
that LSD1 regulate directly the transcription of CCNA2 and ERBB2 through 
demethylation of H3K9, but not by demethylation of H3K4.  
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5.   LSD1 enzyme assay for high-throughput screening 
(HTS) 
 
 
5.1.   Epi-drugs, a new class of cancer therapeutics 
 
In the last years, the pharmacoepigenomic field has highly improved and epi-drugs are 
introduced as a new class of cancer therapeutics. The HDAC inhibitor 
suberoylanilidehydroxamic acid (SAHA) has recently been approved for the treatment of 
advanced T cell lymphoma, while other HDAC inhibitors and DNMT inhibitors are in 
clinical trials (Kuendgen et al., 2008, Spannhoff et al., 2009). Compared to that field of 
epigenetics, the knowledge on histone methylation and the consequences of its 
inhibition is still behind. Also the search for inhibitors is still in the beginning, and to date, 
no specific chemical modulators of endogenous LSD1 have been identified, although 
histone methylation has been shown to be important in epigenetic regulation of gene 
expression through the establishment of stable gene-expression patterns. MAOIs which 
are the first available small molecular inhibitors of LSD1 were shown to be inadequate 
for the tumor treatment due to their excessive side effects such as seizures caused by 
their modulation of neurotransmitter deamination. In this study, I wanted to establish a 
LSD1 enzyme assay for high-throughput screening to identify lead compounds for 
specific LSD1 inhibitors. 
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5.2.   Results 
 
5.2.1.   Cloning and expression of recombinant human LSD1 
 
 
The purification of LSD1 was done in collaboration with Dr. Young-Jun Im (NIH, U.S.A).  
 
 
To establish an in vitro enzyme assay for LSD1, we purified the recombinant human 
LSD1 from E. coli. Firstly, the gene encoding the LSD1 construct (166–852 amino acids) 
was subcloned to pET15b expression vector providing an N-terminal his6-tag for affinity 
purification. The LSD1 expression construct lacks the first 165 amino acids but it 
contains the SWIRM and aminoxidase domains. This construct has previously been 
shown to be active toward peptide substrate in vitro (Forneris et al., 2005). The N-
terminal his6-tagged LSD1 ∆N (166-852) protein was expressed in E. coli BL21 (DE3) 
star by adding 0.75 mM IPTG. The lysate was applied to Ni2+affinity column and the his6-
tagged LSD1 was eluted with the buffer (100 mM Tris HCl pH 8.0, 300 mM imidazole). 
The protein was concentrated to 4 ml and then purified by size exclusion 
chromatography using a Superdex 200 (16/60) column. The fractions containing 
Figure 5.1. Induction and purification of N-terminal his6-tagged LSD1 ∆N (166-852) (1) The 
fusion protein was expressed in E. coli BL21 (DE3) Star overnight at 20°C in the presence of  0.75 – 1 
mM IPTG. (2)  The lysate was applied to Ni2+ affinity column and his-tagged LSD1 was eluted with 
the elution buffer (100 mM Tris-HCl pH 8.0, 300 mM Imidazole). (3) The protein was concentrated 
and then purified on a Superdex 200 (16/60) size-exclusion column in 20 mM Tris-HCl pH 8.0, 100 
mM NaCl. (4) Three fractions were passed through HitrapQ ion exchange column (50 mM Tris pH 
8.0). Finally, purified LSD1 was stored in 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 % Glycerol, 2 mM
DTT. 
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recombinant LSD1 were passed through a HighTrapQ ion exchange column equilibrated 
with the buffer (100 mM TrisHCl pH 8.0), which resulted in the final LSD1 sample with 
purity higher than 95% estimated by SDS-PAGE (Figure 5.1). The purified LSD1 was 
stored in the buffer (20 mM Tris HCl pH 8.0, 100 mM NaCl, 5% glycerol, 2 mM DTT). 
 
 
5.2.2.   Establishment of LSD1-HRP coupled assay for high-throughput screening 
 
 
Recombinant LSD1 (0.25 µM) was incubated with a peptide substrate (10–100 µM) 
representing the N-terminal tail of histone H3 dimethylated at Lys4 
(ART[dimethylK]QTARKSTGGKAPRKQLAGGK-biotin [from N- to C- terminal]). 
Subsequent hydrogen peroxide formation was detected using horseradish peroxidase 
(HRP; 0.4 µM) coupled to fluorogenic electron donor dye Amplex Red (100 µM). The 
resultant product resorufin is a highly fluorescent compound (excitation 544 nm, 
emission 590 nm) (Figure 5.2).  
To analyze the sensitivity and the linear range of the assay, a standard curve using a 
series dilution of hydrogen peroxide was measured (Figure 5.3). In the absence of           
Figure 5.2. LSD1-HRP coupled assay. Recombinant his6-tagged LSD1 (166-852aa; 0.25 µM) 
catalyzes the demethylation reaction of dimethylated histone H3 peptide comprising N-terminal 24 
amino acids (H3K4me2; 35 µM) to H3K4 producing H2O2 as a byproduct. Then, horseradish 
peroxidase (HRP; 0.4 µM) uses Amplex Red (100 µM) as an electron donor during the reduction of 
hydrogen peroxide to water. The resultant product, resorufin, is a highly fluorescent compound 
(excitation 544, emission 590 nm). The reaction was performed in buffer (50 mM HEPES pH 7.5, 
0.1% Triton-X100) at 37 °C. Concentrations represent the end-concentration of the reagents. 
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recombinant LSD1 and a peptide substrate, HRP reduces exogenous hydrogen peroxide 
to water using Amplex Red as an electron donor. The amount of the resulting product 
resorufin is proportional to the hydrogen peroxide concentration. A serial dilution of 
hydrogen peroxide ranging from 0.01 to 20 µM was incubated with HRP (0.4 µM) and 
Amplex Red (100 µM) in 50 mM HEPES buffer, pH 7.5. The linear range lies between 
0.05–20 µM and the linear correlation coefficient (R2) was 0.99. The detection limit was 
estimated as the minimum hydrogen peroxide concentration evoking a response 
significantly different from that of the zero hydrogen peroxide. The detection limit was 
0.05 µM (P < 0.01, n = 3). 
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Figure 5.3. The standard curve using a serial dilution of hydrogen peroxide. Horseradish 
peroxidase (HRP) reduces hydrogen peroxide to water using Amplex red as an electron donor. The 
amount of the resulting product, resorufin (excitation 544 nm, emission 590 nm) is proportional to the 
hydrogen peroxide concentration. A serial dilution of hydrogen peroxide ranging from 0.01 to 20 µM 
was incubated with HRP (0.4 µM) and Amplex Red (100 µM) in 50 mM HEPES buffer, pH 7.5. The 
Linear range was 0.05 – 20 µM and the linear correlation coefficient (R2) was 0.99. The detection 
limit was estimated as the minimum hydrogen peroxide concentration evoking a response 
significantly different from that of the zero hydrogen peroxide. The detection limit was 0.05 µM (P < 
0.01, n=3). Fluorescence value was calculated by subtracting the background fluorescence from 
each value. 
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The approximate concentration of hydrogen peroxide produced by the LSD1 enzyme 
reaction was measured for ~ 1 h and supposed to be less than 5 µM compared the 
standard curve. LSD1-mediated peptide demethylation was very slow, while the HRP-
mediated enzyme reaction occurred very fast, suggesting that the fluorescence 
development only depends on the LSD1-mediated hydrogen peroxide production.  
 
 
 
To adapt the assay to higher throughput, 96 well microplates were used. An overall 
assay volume was adjusted to 40 µL which reduced the amount of reagents. In this 96 
well plate format, a reaction progress curve was obtained to measure initial velocity (V0). 
The inactivation of LSD1 by the addition of 10 or 100 µM tranylcypromine was observed 
with decreased V0 (Figure 5.4).  
 
Using the Michaelis-Menten plot, the Km value for the his6-tagged LSD1 ∆N was 
determined as 35 ± 9 µM (Figure 5.5). Fornes et al. reported a Km of 9–50 µM for the 
same substrate (Fornes et al., 2005; Schmidt et al., 2007). Substrate concentration 
equal to this Km was used in further screening assays.   
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Figure 5.4. Time- and concentration-dependent inactiviation of LSD1 by tranylcypromine. A 
reaction progress curve was obtained by measuring resorufin over 25 min upon mixing 50 µM 
H3K4me2, 250 nM LSD1, 100 µM Amplex red and 0.4 µM HRP in the peroxide coupled assay 
system. The inactivation of LSD1 by 10 and 100 µM tranylcypromine was concluded from a 
decreased initial velocity (V0) represented by decreased slope. Fluorescence value was calculated 
by subtracting the background fluorescence from each value.
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The known LSD1 inhibitor tranylcypromine served as a reference compound in further 
experiments. In order to determine appropriate ranges of inhibitor concentrations to be 
used in screening assays, a dose-response experiment was performed with 
tranylcypromine (Figure 5.5). LSD1 had been preincubated with tranylcypromine for 5 
min at RT and then the assay was initiated by the addition of peptide substrate. The 
inhibitory concentration yielding 50% decrease in initial velocity (IC50) for 
tranylcypromine was 57 µM (95% confidence intervals: 26–117 µM). This value was 
higher than the IC50 value of 20 µM which had been reported (Schmidt et al., 2007). 
Since tranylcypromine is an irreversible inhibitor of LSD1, rendering IC50 determinations 
is highly dependent on assay conditions and useful only as a reference point for further 
experiments (Schmidt et al., 2007). 
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Figure 5.5. (A) Determination of Km value for recombinant LSD1. Km value for his6-tagged 
recombinant LSD1 ∆N was measured as 35 ± 9 µM (95% confidence intervals (CI): 16.80 ~ 53.63 
µM). (n = 3)  (B) Determination of IC50 for tranylcypromine Tranylcypromine, a known LSD1 
inhibitor was used as a reference compound in further screening assays. Inhibitory concentration 
yielding 50 % inhibition (IC50) for tranylcypromine was 57 µM (95% CI: 26–117 µM) Fractional 
activity (Y axis; V0 [tranylcypromine X µM]/ V0 [tranylcypromine 0 µM] is plotted as a function of 
inhibitor concentration (X axis).  
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5.2.3.   Chemical screening for LSD1 inhibitors 
 
In cooperation with Prof. Dr. H. Waldmann of the Max-Planck-Institute (Dortmund), a 
compound collection comprising 768 substances was subjected to the LSD1-HRP 
coupled assay. This compound library was designed and prepared primarily for the 
screening of new MAO inhibitors using a cheminformatics approach. Given that the 
LSD1 catalytic domain has sequence homology with MAO enzymes, we anticipated that 
some compounds would inhibit LSD1 but have little potency on MAOs.  
 
 
 
Since all compounds were solubilized in DMSO, final 2.5 % of DMSO which did not 
affect the in vitro assay was incubated in every screening plate. The positive control, 
negative control and reference control were also included in every screening plate. The 
positive control contained recombinant LSD1, peptide substrate, Amplex Red and HRP, 
whereas peptide substrate was excluded in the negative control. The reference control 
included tranylcypromine and all other reagents (Figure 5.6).   
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Compound 1 (concentrations: 50, 10, 2, 0.4 µM)
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Figure 5.6. Establishment of the high-throughput screening assay. (A) The pipetting plan in 
the 2nd screening was illustrated. LSD1 was screened against a compound collection. Each 
compound was diluted in 4 different concentrations (0.4, 2, 10, 50 µM). The positive control 
contained LSD1, peptide substrate, Amplex red and HRP, except for the inhibitor. The negative 
control contained neither substrate nor inhibitor. Tranylcypromine was used as a reference 
compound. (B) The readout of each well in the 96 microplate is done by detection of fluorescence 
intensity in a time-dependent manner.  
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Whole screenings were accomplished in 3 steps (Figure 5.7). In a primary screening, 
compounds were tested at a concentration of 50 µM to cover weakly active molecules as 
well. 80 compounds were found as positive hits. In a secondary screening, the following 
80 compounds were tested at 4 different concentrations (0.4, 2, 10 and 50 µM) to 
validate their inhibitory effects. During screening, some benzopyrone derivative 
compounds were found to be capable of reacting directly with hydrogen peroxide 
produced in the LSD1-mediated enzyme reaction, interfering with the HRP-coupled 
Amplex red oxidation. These redox-sensitive compounds appeared to scavenge 
hydrogen peroxide resulting in decreased conversion of Amplex red to fluorogenic 
resorufin. To eliminate these false positives, the additional experiment was designed in 
which reactivity of the compounds with 5 µM hydrogen peroxide was tested (detailed 
data is shown in Appendix A). Some benzopyrone derivatives having catechol moiety 
turned out to be highly reactive with hydrogen peroxide. 
 
 
1st screening
Compounds were tested at 50 µM and inhibitory 
effects of compounds were screened: 80 compounds 
were selected for the further study.
2nd screening
80 compounds were tested at 4 different 
concentrations (0.4, 2, 10, 50 µM).
Compounds which directly reacted with H2O2, thus, 
interfering with the assay were excluded: 
24 compounds were selected for the further study.
Validation of candidate compounds
in vitro demethylase assay followed by western blotting 
were used to validate the inhibitory effect of 24 
compounds selected by HRP-coupled assay: 
7 compounds were shown to inhibit LSD1.
Figure 5.7. Workflow of screening the large compound library. A 768 compound collection was tested in 3 
steps. 
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After excluding false positives, 24 compounds were selected for the third step. To 
validate the inhibitory activity of identified hits, the follow up screens included western 
blot detection followed by the in vitro demethylase assay. Ten µg of bulk histones were  
 
used as substrate for 1 µg recombinant LSD1 in the in vitro demethylase assay. The 
demethylation of H3K4 in bulk histone was detected by Western blotting using the α-
H3K4me2 antibody (Figure 5.8). Seven compounds were confirmed to inhibit LSD1 
enzyme activity either in LSD1-HRP coupled assay or in the in vitro demethylase assay 
/Western blot (table 5.1). Among the 24 compounds, the remaining 17 compounds 
showed no or very weak inhibitory effect in the in vitro demethylase assay/Western blot 
analysis. While the LSD1-HRP coupled assay used the oligo-peptide corresponding to 
the N-terminal 24 amino acids of histone H3 as a substrate, the in vitro demethylase 
assay used the intact bulk histones which contain whole histone H3. It seems that 
certain compounds could not strongly inhibit the LSD1 enzyme activity on intact bulk 
histones. Alternatively, immunodetection of di-methylated substrate seems to be more 
reliable than HRP-coupled fluorescence-based assay excluding false positives.  
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Figure 5.8. in vitro demethylase assay. Seven compounds (P2A1, P4G19, P5O11, P5O17, 
P6A15, P6A3, P8K9) were found to have inhibitory effect against LSD1 at a concentration of 50 
µM. (– LSD1) and (+ LSD1) serve as controls; (+ LSD1) contains either 1 µg LSD1 enzyme or 10 
µg bulk histone as the substrate, while (– LSD1) contains only 10 µg bulk histone in 50 mM 
hepes buffer. In the presence of LSD1 (+ LSD1), methylated H3K4 in bulk histone was 
demethylated by LSD1. Tranylcypromine (TCM) serves as a reference compound. Histone H3 
was used as the loading control.
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As shown in Table 5.1, most compounds showed concentration-dependent inhibitory 
effects except tranylcypromine and P8K9. It may reflect the low accuracy of a microplate 
system. Alternately, the inhibitory effect by compounds may be caused by other factors 
independent on the enzyme inhibition.  
In cooperation with Prof. Dr. R. Schüle from Freiburg Medical School (Freiburg), the 
inhibitory capability of the final 7 compounds was further investigated using mass-
spectrometry which can analyze the change in methylation status of the peptide 
substrate after the in vitro enzyme reaction. Ultimately, only the compound P2A1 was 
confirmed as a putative LSD1 inhibitor among the 7 compounds. It remains to be 
elucidated why the other 6 compounds were proven to be negative in mass spectrometry. 
Further studies are needed to validate the assay results and inhibitory capability of 
compounds not only in the in vitro system but also in cell based experiments. 
 
P8K9                  0.53       0.53       0.58       n.d.     +++                     -
P6A3                  0.78       0.63       0.62      0.49      ++                       -
P6A15                0.50       0.51       0.48      0.36       +                        -
P5O17                0.80       0.47       0.44      0.11       +                        -
P5O11                0.45       0.36       0.15      0.05       ++                       -
P4G19                0.47       0.49       0.39      0.24       +                       -
P2A1                  0.60       0.67       0.50      0.26      ++               LSD1 inhibitor   
compounds       Inhibitory effects in LSD1-HRP assay                       in vitro assay                                 
(No.)                 (Relative decrease in initial velocity) followed by WB         followed by MS§
0.4 µM     2 µM      10 µM     50 µM                     50 µM*                     50 µM
Table 5.1. List of final 7 compounds. The 7 compounds were found to have inhibitory 
effects in LSD1-HRP coupled enzyme assay and in the in vitro demethylase 
assay/western blot (WB). Mass spectromery (MS) showed, however, only P2A1 as a 
putative LSD1 inhibitor. Relative decrease in initial velocity was calculated at 4 different 
concentrations of compounds. *The inhibitory effect shown by the in vitro demethylase 
assay was arbitrarily described as +. §Mass spectrometry was done in cooperation with 
Prof. Dr. R. Schüle in Freiburg (data not shown).
Tranylcypromine 0.34       0.53       0.52      0.35                    +++  -
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6.   Discussion 
 
 
6.1.   LSD1 in neuroblastoma 
 
6.1.1.   LSD1 expression correlates with cell differentiation and growth in 
neuroblastoma 
 
Our data clearly indicate that LSD1 expression inversely correlates with differentiation of 
primary neuroblastic tumors and is related to poor clinical outcome. Similar results were 
recently reported by Kahl et al. for prostate cancer (Kahl et al., 2006). Moreover, Wang 
et al. (Wang et al., 2007) reported that under physiological conditions high LSD1 
expression is characteristic of undifferentiated progenitor cells. Consistently, in vitro 
differentiation of neuroblastoma cells resulted in down-regulation of LSD1. In addition, 
inhibition or knock-down of LSD1 led to cell differentiation by induction of differentiation 
associated genes TNS1, TPM1, DNM2 and DNAL4 and reduced cell proliferation. 
Although the molecular mechanism regarding the role of LSD1 in cell differentiation is 
not well understood, these data suggest that aggressive, undifferentiated cancer cells 
retain a high level of LSD1 expression, which is a characteristic of undifferentiated 
progenitor cells. 
 
 
6.1.2.   Specificity and regulatory mechanism of LSD1 are cellular complex 
dependent 
 
LSD1 modulates demethylation of mono- and di-methyl-lysines at residues 4 or 9 in 
histone H3 (Stavropoulos et al., 2007). Specificity of demethylation is governed by the 
interaction partners of LSD1. LSD1 was previously found to be part of the chromatin 
modifying Co-Rest complex. The REST/Co-Rest complex, which includes LSD1 and 
HDAC1/2, is recruited to the promoters of neuronal-specific genes, and specifically 
represses the genes by epigenetic silencing (Lakowski et al., 2006; Lee et al., 2005). 
Recently, REST also called neuron restrictive silencer factor, was demonstrated to be 
down-regulated upon neuroblastoma cell differentiation (Di Toro et al., 2005). Therefore, 
highly active LSD1 in the REST/Co-Rest complex might repress a neuronal 
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differentiation program in neuroblastoma, and the differentiation program would be in 
part re-activated upon decrease of LSD1 level and REST/Co-Rest activity. Depending 
on cellular context, LSD1 also directly interacts with transcription factors and 
demethylates lysine residues in the promoter regions of specific genes. This has been 
shown for the interaction of LSD1 with the androgen receptor (Wissmann et al., 2007). 
Thus, LSD1 dependent suppression of the neuronal differentiation program in 
undifferentiated neuroblastoma cells might be mediated by the recruitment of LSD1 
protein by both transcription factors and co-repressors. 
 
 
6.1.3.   Epigenetic therapy may serve as an alternative to targeting transcription 
factors 
 
In neuroblastomas, MYCN is known to be a central oncogene that regulates expression 
of cell cycle related genes. However, pharmacological intervention to modulate 
transcription factors like MYCN has not yet been achieved. As discussed above, LSD1 is 
involved in the regulation of broad gene expression programs that maintain the 
aggressive, undifferentiated phenotype in neuroblastoma. While this functionality is 
shared by LSD1 and its cooperating transcription factors, LSD1 and other histone-
modifying enzymes additionally have intrinsic enzymatic activities. Thus, they can be 
considered as good pharmacological targets for small molecule inhibitors. LSD1 has 
recently been identified as a target for MAO inhibitors, including tranylcypromine, which 
are already in clinical use to treat depression (Huang et al., 2007; Yang et al., 2007; Lee 
et al., 2006; Stavropoulos et al., 2007).  
 
 
6.1.4.   Do MAO inhibitors qualify as LSD1 inhibitors in a clinical setting? 
 
As MAOI are the first available small molecular inhibitors of LSD1 (Culhane et al.,  2007; 
Yang et al., 2007), we analyzed their effectiveness against neuroblastoma cells. While 
they appeared to be very effective in vitro, relatively high doses were required to reduce 
the growth of xenograft tumor in animal models. The doses required to suppress tumor 
cells were higher than those effectively inhibiting neurotransmitter deamination, resulting 
in significant side effects such as seizures in the treated mice. For this reason, we do not 
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expect the currently available MAO inhibitors to be clinically applicable as LSD1 
inhibitors. Instead, specific LSD1 inhibitors need to be developed, which do not inhibit 
the type A and B monoaminoxidases (see below). The development of small molecules 
modulating substrate specificity appears plausible when the surprising capability of 
LSD1 to change substrate specificity between H3K4 and H3K9 is taken into 
consideration, which might well be the effect of allosteric conformational switches 
(Stavropoulos et al., 2007). 
 
 
6.1.5.   Multimodal epigenetic therapy might be applicable as targeted therapy 
 
At present, rational tumor therapy aims to target the hallmarks of cancer cells by 
inhibiting angiogenesis, blocking anti-apoptotic proteins and inhibiting tumor-associated 
receptor tyrosine kinases that generate survival signals. Most often, tumor cells 
circumvent such therapeutic interventions either by mutation of the target structures or 
by activation of alternative pathways. We have observed such secondary mutations in 
response to imatinib therapy of gastrointestinal tumors (Wardelmann et al., 2005). The 
problem of resistance to targeted therapies certainly needs to be addressed in 
multimodal strategies. Therefore, it is of great importance that reprogramming of tumor 
cells appears possible via interference with enzymes manipulating epigenetic patterns. A 
combination of histone demethylases and HDAC inhibitors might prove useful to prevent 
the development of resistance to treatment and achieve a maximal effect Indeed, 
inhibition of LSD1 and HDAC turned out to be synergistic for epigenetic regulation (Lee 
et al., 2006). Furthermore, LSD1 and the jumonji domain family of proteins such as 
JMJD2C were reported to cooperate to stimulate the expression of androgen receptor-
dependent genes (Wissmann et al., 2007). Taken together, this suggests that the 
combination of inhibitors of different histone demethylases might act synergistically to 
reprogram gene expression signatures underlying the malignant phenotype of tumor 
cells.  
In summary, we provide the first evidence that LSD1 may serve as a drug target in 
neuroblastoma, and that LSD1 inhibitors alone or in combination with other chromatin-
modifying agents may provide potential therapeutic options to reprogram the malignant 
phenotype of neuroblastoma and possibly other aggressive cancers with features of 
undifferentiated progenitor cells. 
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6.2.   LSD1 in breast cancer 
 
6.2.1.   Establishment of an ELISA for screening LSD1 levels in tumor tissues 
 
In our previous works on prostate cancer and neuroblastoma, aberrantly high LSD1 
expression in tumor revealed to provide a powerful marker for aggressive cancers with 
poor prognosis. Reliable and efficient detection of this marker would be of importance for 
its application in tumor diagnosis, and above all, for large screening of human tissue 
samples. Immunohistochemistry is the standard method to analyze the specific protein 
level of tissue samples but it is only a semi-quantitative method which requires 
independent examinations by two pathologists. Here, I established a novel direct ELISA 
to quantify the LSD1 protein level in patient tumor tissues. In this direct ELSIA, tissue 
extracts were directly coated on the 96 well microplate and incubated with a monoclonal 
antibody which detects the protruding tower domain of LSD1 protein. Using this LSD1 
ELISA, I could detect that the LSD1 protein level in tumor region of ER-negative breast 
cancer is highly upregulated compared to that in matched normal tissues. The following 
immunohistochemistry and Western blot analysis validated the ELISA results. This new 
established ELISA is also useful to detect LSD1 protein amount in other tumor entities; 
for example, a limited number of neuroblastoma specimens was subjected to the ELISA 
to determine the LSD1 protein level. 
 
 
6.2.2.   LSD1 is highly expressed in hormone receptor-negative breast cancers 
 
Several prognostic and predictive biomarkers are currently used to stratify patients with 
breast cancers for appropriate chemotherapies. Established biomarkers such as ER and 
PR already play a significant role in the selection of patients for endocrine therapy. In 
this study, we demonstrate that high expression levels of LSD1 may serve as a novel, 
molecular marker for malignant breast tumor. By different methods, I could show that 
LSD1 is significantly stronger expressed in ER-negative breast cancers which are well 
known to carry a poorer prognosis than ER-positive tumors (Cui et al., 2005). Alteration 
in LSD1 expression appears not to be linked specifically to breast cancer. Importantly, 
aggressive, undifferentiated cancer cells appear to retain a high level of LSD1 
expression. Recently, our group found that LSD1 expression is up-regulated in high-risk 
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prostate cancers with aggressive biology (Kahl et al., 2006). In neuroblastomas, LSD1 
expression was strongly associated with adverse outcome and inversely correlated with 
differentiation (Schulte et al., 2009). Taken together, this study provides additional 
evidence that LSD1 can serve as a promising molecular marker for aggressive tumor 
biology. 
 
 
6.2.3.   LSD1 contributes to cell proliferation through regulation of CCNA2 and 
ERBB2 
 
ER-negative tumors are characterized by their rapid growth, loss of differentiation and 
acquisition of invasive and metastastic capability. The detailed mechanism by which 
LSD1 overexpression contributes to neoplastic conversion of tumor cells remains to be 
elucidated. A recent study indicated that LSD1 might promote G2-M phase transition and 
cell proliferation, which is one way in which its overexpression might promote 
tumorigenesis (Scoumanne et al., 2007). Here, in vitro silencing of LSD1 has shown to 
inhibit tumor cell-growth by down-regulating genes involved in proliferation. ChIP 
revealed that LSD1 was recruited to the CCNA2 and ERBB2 promoter, accompanied by 
a significant and highly reproducible increase in histone H3K9me2 upon knock-down of 
LSD1. Therefore, CCNA2 and ERBB2 seem to be direct, positively regulated targets of 
LSD1 in breast cancer cells. CCNA2 encodes Cyclin A2 which functions as an activator 
of CDK2 kinase, and thus promotes both G1/S and G2/M cell cycle transitions. Hence, 
CCNA2 up-regulation by LSD1 may be one important mechanism by which LSD1 drives 
tumorigenesis and aggressive biology of breast cancers. Indeed, abnormal 
overexpression of cyclin A2 corresponds to an increase in the proliferative status of 
tumor cells and may play an important role in tumor development and progression 
(Fraczek et al., 2008; Patel et al., 2007). However, we did not find a significant 
correlation of LSD1 with HER2 overexpression in breast tumor specimens in vivo, 
although in vitro study showed that LSD1 positively regulates ERBB2. It appears that 
additional mechanisms, such as gene amplification are dominant events in HER2-
positive tumors (Sunami et al., 2008). 
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6.2.4.   LSD1 functions in association with other transcriptional 
cofactors/epigenetic enzymes 
 
LSD1 known as a histone H3K4 and H3K9 di- and mono-demethylase acts as a 
functional component of either co-activator or co-repressor complexes and regulates 
activation and repression programs. Transcriptional regulation by LSD1 is known to be 
cell type specific and the substrate specificity of LSD1 can be modulated by its 
associated partners such as hormone receptors (AR or ER) (Wissmann et al., 2007; Shi 
et al., 2005). LSD1 appears to regulate transcription of ERBB2 and CCNA2 possibly in 
concert with other genetic/epigenetic factors. As shown by qRT-PCR analysis, silencing 
of LSD1 caused a partial repression of gene transcription and induced the enrichment of 
H3K9 methylation in the promoter regions. In case of CCNA2 or ERBB2, E2F and AP2 
transcription factors are known to be positive regulators of gene transcription, 
respectively (Chen et al., 2004; Pellikainen et al., 2007). It is therefore possible that, in 
the presence of corresponding stimuli and/or in combination with knock-down of other 
epigenetic enzymes, silencing of LSD1 would induce even stronger down-regulation of 
its target genes. Therefore, the mechanism of LSD1 activity on H3K9 in partnership with 
other transcriptional co-factors needs to be addressed in the further study.  
 
 
6.2.5.   Targeting LSD1 in breast cancer provides a novel therapeutic option 
 
Aberrant expression of LSD1 in ER-negative breast tumor and its function in driving 
CCNA2 overexpression suggest that LSD1 may not only serve as a biomarker for 
malignant breast tumors, but also as a therapeutic target in cancer treatment. While ER-
positive breast tumors respond well to anti-hormonal therapy, the treatment of ER-
negative breast tumors usually includes chemotherapy by non-selective cytotoxic drugs. 
Targeting LSD1 in ER-negative breast cancer might provide an alternative, more specific 
treatment. 
Both MAOI and polyamine analogues have been shown to inhibit LSD1 enzymatic 
activity (Metzger et al., 2005; Lee et al., 2006; Huang et al., 2007). Polyamine analogues 
cause re-expression of aberrantly silenced genes that are important in the development 
of colon cancer (Huang et al., 2007). The level of re-expression of these otherwise 
silenced genes was almost 30% of that observed after treatment with DNA-
Discussion  
 
 63 
methyltransferase inhibitors which are of great therapeutic interest but have many side 
effects. If LSD1 inhibition leads to significant de-repression of some of the same genes 
that are reactivated by DNA-methyltransferase inhibitors, LSD1 might be an important 
alternative target for therapy. Consistenly, we recently provide direct evidence that LSD1 
is a target in cancer therapy. In a xenograft mouse model, MAOIs significantly 
decreased neuroblastoma tumor growth (Schulte et al., 2009). In combination with the 
novel data of this study we hypothesise that LSD1 inhibitors alone or in combination with 
DNA demethylating drugs or/and chromatin-modifying agents might prove effective for 
treatment of hormone receptor-negative aggressive breast cancer. 
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6.3.   LSD1 enzyme assay for high-throughput 
 
6.3.1.   The LSD1-HRP coupled assay can be applied for high-throughput kinetic 
study 
 
To identify selective LSD1 inhibitors from a compound library comprising 768 natural 
compounds, we have developed a fluorescence-based in vitro LSD1 enzyme assay. The 
fluorescence-based LSD1-HRP coupled assay turned out to be much more sensitive 
than the standard colorimetric LSD1-HRP coupled assay (Yang et al., 2007; Szewczuk 
et al., 2007; Schmidt et al., 2007). In the fluorescence-based system, the reaction 
volume could be minimized to 40 µl requiring only small amounts of peptide substrate 
and recombinant LSD1 protein. Moreover, using 96 well microplates, kinetic studies of 
each well could be done at the same time. Despite the lower accuracy of a microplate 
system, the assay system was shown to be efficient for primary screening of large 
compound libraries.  
 
However, the concern must be addressed to some benzopyrone derivatives which might 
interfere with the HRP-coupled assay which detects hydrogen peroxide or have auto-
fluorescence themselves. In combination with alternative assays such as demethylation 
detection using immunoblotting or biochemical test on the reactivity of compounds with 
hydrogen peroxide, false positive hits were excluded and the specificity of the hits could 
be validated (Appendix A). However, for the screening of large-scale compounds, this 
could be a limiting factor for high-throughput screening. The design of new assays that 
do not use hydrogen peroxide would be desirable especially for the screening of redox-
sensitive compounds. For example, PRMT1 inhibitor screening was done using the 
ELISA-based screening in which methylated arginine-substrate was detected using 
specific primary antibody and HRP-labeled secondary antibody. This assay has the 
disadvantage that kinetic measurements are not possible, but it would be useful for the 
primary high-throughput screening (Chen et al., 2004).  
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6.3.2.   The LSD1-HRP coupled assay identified a putative LSD1 inhibitor 
 
In this study, at least 1 putative LSD1 inhibitors was identified. In collaboration with Prof. 
R. Schüle (Freiburg) and Prof. H. Waldmann (Dortmund), P2A1 was identified as a 
possible lead compound for the following reasons: 1) it inhibits LSD1 but not MAO; 2) it 
is cell-permeable; 3) it has a good solubility. The further studies are planned to test 
whether it can inhibit endogenous LSD1 activity. In this cell-based experiment, for 
example, accumulation of H3K4 dimethylation, reactivation of aberrantly repressed 
tumor suppressor genes and anti-proliferative effect by the compound will be analyzed. 
Ultimately, xenograft mouse models would be useful to evaluate anti-tumor effect of the 
inhibitor in vivo. The identification of a putative LSD1 inhibitor may serve as a starting 
point toward the development of a new class of a LSD1 selective inhibitor.  
 
 
6.3.3.   Is LSD1 a promising drug target for cancer therapy? 
 
Epigenetic drugs, whether demethylating agent or HDAC inhibitor, target aberrantly 
heterochromatic regions leading to reactivation of tumor suppressor genes and/or other 
genes that are crucial for the normal functioning of cells. Some concerns were given 
regarding the modulation of histone methylation. The methyl marks exist as both active 
and inactive markers, and it might therefore be difficult to determine whether inhibiting a 
histone demethylase such as LSD1 would be beneficial for patients because the enzyme 
has opposing effects on gene regulation.  
However, our experiment using a xenograft mouse model revealed for the first time that 
targeting LSD1 could inhibit xenograft tumor growth in vivo. Moreover, there are some 
considerations that LSD1 could be an attractive target in tumor therapy: (i) LSD1 
expression is linked to tumors with aggressive biology, while some other epigenetic 
enzymes such as G9a have not been directly involved in tumorigenesis. Our data and 
other reports have shown that aberrant expression of LSD1 increases considerably 
when tumors enter advanced stages (Schulte et al., 2009; Kahl et al., 2006). 
Disequilibrium caused by epigenetic disregulations in tumor cells seems to promote 
tumorigenesis. Thus, LSD1 inhibition may selectively delay the growth of tumor cells 
overexpressing LSD1; (ii) LSD1 inhibitors can be useful for the treatment of hormone-
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dependent cancers. For example, LSD1 assembles into the AR complex and regulates 
AR target gene transcription. LSD1 inhibition was shown to be capable of antagonizing 
AR action preventing hormone-induced tumor growth (Metzger et al., 2005). Thus, 
targeting LSD1 can be an alternative strategy for the treatment of cancers that are 
hormone-dependent or resistant to hormone-therapy; (iii) in light of the fact that 
HDAC1/2 and LSD1 activities are synergistic with regards to transcriptional inhibition, 
inhibition of LSD1 will likely result in a profound effect on transcription like the inhibition 
of HDACs. Indeed, LSD1 inhibitors were shown to be capable of reactivating the 
pathologically silenced tumor suppressor genes in colon cancer cells (Huang et al., 
2007). Combination of LSD1 inhibitors with HDAC inhibitors might be advantageous to 
achieve synergistic tumor-cell growth inhibition and gene reexpression.  
 
 
6.3.4.   Epigenetic therapy can be used in combination with other therapeutic 
modalities.  
 
Epigenetic drugs can be therapeutically used alone or as part of a combination with 
other therapeutic modalities, such as chemotherapy, immunotherapy or radiotherapy. So 
far, a number of preclinical studies have demonstrated that either DNA methylation or 
histone deacetylase inhibitors reverse drug resistance or increase the cytotoxicity of 
anticancer drugs and radiation (Mai et al., 2009). In this regard, a number of clinical trials 
are currently testing epigenetic drugs either alone or in combination with conventional 
cytotoxic and radiation therapy.  
Therefore, the development of LSD1 selective inhibitors would help to evaluate the 
therapeutic potential of targeting LSD1 as well as their use in combination with other 
therapeutic modalities for tumor therapy.  
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7.   Materials and methods 
 
 
7.1.   Material 
 
7.1.1.   Chemicals 
Acrylamide (Rotiphorese Gel 30) Carl Roth GmbH, Karlsruhe 
Agar Merck, Darmstadt 
Agarose Sigma Aldrich, St. Louis, USA 
3-amino-9-ethyl-carbazolke Dako, Glostrup, Dänemark 
Ammonium peroxisulfate (APS) Carl Roth GmbH, Karlsruhe 
Ampicillin Carl Roth GmbH, Karlsruhe 
Amplex Red Invitrogen, Karlsruhe 
Aquatex Merck, Darmstadt 
Blocking reagent (for ELISA) Roche Diagnostics, Mannheim 
Blocking reagent (for IHC) DAKO, Glostrup, Dänemark 
Bovine serum albumin (BSA) Sigma Aldrich, St. Louis, USA 
Bulk histone  Sigma Aldrich, St. Louis, USA 
Clorgyline Sigma Aldrich, St. Louis, USA 
Complete Mini Roche Diagnostics, Mannheim 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, St. Louis, USA 
dNTPs Invitrogen, Karlsruhe 
Dulbecco´s MEM Invitrogen, Karlsruhe 
Dynabead Invitrogen, Karlsruhe 
ECL reagent Perbio, Bonn 
Ethanol Merck, Darmstadt 
Ethidium bromide Sigma Aldrich, St. Louis, USA 
Fetal calf serum Invitrogen, Karlsruhe 
Glycerol Sigma Aldrich, St. Louis, USA 
Glycine Sigma Aldrich, St. Louis, USA 
H2O2 Sigma Aldrich, St. Louis, USA 
HEPES Sigma Aldrich, St. Louis, USA 
HiPerFect Qiagen, Hilden 
Horse radish peroxidase (HRP) Sigma Aldrich, St. Louis, USA 
Imidazole Sigma Aldrich, St. Louis, USA 
Isopropanol Sigma Aldrich, St. Louis, USA 
IPTG Merck, Darmstadt  
Kanamycin Carl Roth, Karlsruhe 
Mayer´s hematoxylin Sigma Aldrich, St. Louis, USA 
Methanol Merck, Darmstadt 
MTT            Sigma Aldrich, St. Louis, USA 
NP-40 Calbiochem, Darmstadt 
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Pargyline Sigma Aldrich, St. Louis, USA 
Penicillin/Streptomycin Invitrogen, Karlsruhe 
RNase-Off Invitrogen, Karlsruhe 
Roti-load 4x concentrate Carl Roth, Karlsruhe 
RPMI 1640 Invitrogen, Karlsruhe 
Salmon sperm DNA Invitrogen, Karlsruhe 
siRNA                                                                     Ambion, Austin, USA; Qiagen, Hilden 
Sodium bicarbonate/carbonate Sigma Aldrich, St. Louis, USA 
Sodium chloride Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Merck, Darmstadt 
Skim milk powder Sigma Aldrich, St. Louis, USA 
Sulphuric acid (2N) Sigma Aldrich, St. Louis, USA 
Synthetic peptide  CASLO, Lyngby, Denmark 
TEMED Bio- Rad, Hercules, USA 
TMB substrate for ELISA Pierce, Rockford, USA 
Tranylcypromine Biomol, Hamburg 
Trishydroxymethylaminomethane (Tris) Merck, Darmstadt 
Triton-X100 Sigma Aldrich, St. Louis, USA 
Trypsin EDTA (0.25% / 0.02%) Invitrogen, Karlsruhe 
Tween-20 Sigma Aldrich, St. Louis, USA 
X-Gal Invitrogen, Karlsruhe 
 
All chemicals listed here are the molecular biology grade.  
 
 
7.1.2.   Apparatus 
 
Abiprism 7900HT  Applied Biosystems, Foster City, USA 
AxioCam digital camera  Zeiss, Oberkochen 
Bacteria shaker Innova 4000 New Brunswick Scientific, Nürtingen 
Centrifuges 5415D Eppendorf, Hamburg 
Centrifuges 5417R Eppendorf, Hamburg 
Cryostat (CM 3050 S) Leica, Wetzlar 
Digital camera KY-F70B JVC, London, UK 
ELISA Reader ELx800  BioTek Instruments, Winooski, USA 
Enzyme kinetic plate reader BMG LABTECH´s FLUOstar OPTIMA, Offenburg 
FastPrep FP120 instrument MP Biomedicals, Irvine, USA  
Hoefer Dual Gel Caster Amersham Bioscience, Freiburg 
Kodak X- omat 1000 Processor Kodak, Rochester, USA 
Magnetic stirrer Ika-Combimag RCT, IKA-Werke GmbH, Staufen 
Membrane pump M72C, Vacubrand GmbH & Co, Wertheim 
Microscope Axioscop50 Zeiss, Oberkochen; Leica, Wetzlar 
Mighty Small II for 8x7cm Gels Amersham Bioscience, Freiburg 
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Nano Drop  Peqlab Biotechnologie, Erlangen 
Peltier Thermocycler- 200  
(PCR Cycler) 
MJ Research, Waltham, USA 
pH-meter MP 220, Mettler Toledo, Greifensee, Switzerland 
Pipettes Gilson Pipetman, Langenfeld 
Eppendorf, Hamburg 
Power supplies E143 Consort, Turnhout, Belgien 
Shakers Series 25 New Brunswick Scientific CO., Inc. , Edison, 
USA 
Multitron, Infors AG, Bottmingen, Switzerland 
Sterilbench Biohazard, Gelaire, Mailand, Italy 
Heraeus-Christ, Hanau 
Thermomixer compact Eppendorf, Hamburg 
TransBlot Semi-Dry Transfer  Bio- Rad, Hercules, USA 
UV-imaging system Intas UV system, Göttingen 
UV-transilluminator Biometra, Göttingen 
Water purification Millipore-Pelicon Filtration device  
with polysulfone filter cassette 
PTGC, 10000 MW, Millipore, Molsheim, France 
 
 
7.1.3.   Consumables 
 
12, 24, 48 and 96 well cell plates Costar, Lowell, USA 
75T cell culture plate Costar, Lowell, USA 
96 well MaxiSorb plate  Nunc, Wiesbaden 
Autoradiography film Kodak, New Haven, USA 
Bacterial culture tubes Costar, Lowell, USA 
Cell culture plates Costar, Lowell, USA 
Cryo Tube™ Nunc, Wiesbaden 
Eppendorf reaction tubes Eppendorf, Hamburg 
Falcon 2052 Costar, Lowell, USA 
PCR tubes Eppendorf, Hamburg 
Petri dish (bacterial) Costar, Lowell, USA 
Transfer membrane Millipore, Billerika, USA 
Whatman paper Schleicher & Schuell GmbH, Dassel 
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7.1.4.   Antibodies 
 
Mouse-monoclonal antibody ß-Actin (AC15) Sigma Aldrich, St. Louis, USA 
Rabbit-monoclonal antibody H3K4me2 (Y47) Abcam, Cambridge, UK 
Rabbit-monoclonal antibody H3K9me2 (mAbcam1220) Abcam, Cambridge, UK 
Mouse-polyclonal antibody Her2 Dako, Glostrup, Dänemark 
Rabbit-polyclonal antibody Histone H3 Abcam, Cambridge, UK 
Mouse-monoclonal antibody LSD1 (1B2E5) Novus Biological, Littleton, USA 
Goat polyclonal antibody anti-rabbit HRP conjugate Dako, Glostrup, Dänemark 
Goat polyclonal antibody anti-mouse HRP conjugate Dako, Glostrup, Dänemark 
 
 
7.1.5.   Kits 
 
Dako EnVision AEC kit Dako, Glostrup, Dänemark 
Plasmid isolation Qiagen, Hilden 
RNeasyMini kit, Qiagen, Hilden 
QIAquick Gel extraction kit Qiagen, Hilden 
QIAquick PCR purification kit Qiagen, Hilden 
SYBR® Green Taq PCR Mix
TM
 Invitrogen, Karlsruhe 
TOPO TA cloning® Invitrogen, Karlsruhe 
 
 
7.1.6.   Enzymes and markers 
 
Alkaline phosphatase New England BioLabs, Frankfurt 
DNA 100bp ladder Invitrogen, Karlsruhe 
DNA 1kb ladder Invitrogen, Karlsruhe 
DNase I Applera GmbH,Darmstadt 
EcoRI New England BioLabs, Frankfurt 
Prestained SDS- PAGE standards Invitrogen, Karlsruhe 
Proteinase K Invitrogen, Karlsruhe 
Superscript II RT (200 U) Invitrogen, Karlsruhe 
T4 DNA Ligase Invitrogen, Karlsruhe 
Taq DNA polymerase Invitrogen, Karlsruhe 
XhoI New England BioLabs, Frankfurt 
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7.1.7.   Vectors 
 
Table 7.1. Vectors used for the cloning of recombinant LSD1 expression vector  
Vector Description Source 
pET15b N-terminal his6-tag expression vector  Institute of Pathology 
pCMX-Flag-LSD1 Plasmid containing LSD1 gene gift from Prof. R. Schüle 
pCR®II-TOPO® LacZa, Sp6/T7 promoter, MCS, AmpR, KanR Invitrogen, Karlsruhe 
 
 
7.1.8.   Primer sequences 
 
All oligonucleotide primers were synthesized by Invitrogen (Karlsruhe). 
 
Table 7.2. Primers used for the cloning, qRT-PCR and ChIP assay  
 
Name Forward (for) 
Reverse (rev) 
Primer sequence 5' - 3' 
18s rRNA (qRT-PCR) for cgattggatggtttagtgagg 
18s rRNA (qRT-PCR) rev agttcgaccgtcttctcagc 
CCNA2 (qRT-PCR) for ggtactgaagtccgggaacc 
CCNA2 (qRT-PCR) rev gtgacatgctcatcatttacagg 
CCNA2 -70 proximal promoter (ChIP) for cctgctcagtttcctttggt 
CCNA2 -70 proximal promoter (ChIP) rev atcccgcgactattgaaatg 
DNAL4 (qRT-PCR) for gaccttccctctggtcagg 
DNAL4 (qRT-PCR) rev ggctgtgacacatagctcca 
DNM2 (qRT-PCR) for gactgccgagtcactgtcct 
DNM2 (qRT-PCR) rev ttgtccagaggcagcatgta 
ERBB2 (qRT-PCR) for gggaaacctggaactcacct 
ERBB2 (qRT-PCR) rev ccctgcacctcctggata 
ERBB2 -250 proximal promoter (ChIP) for ggcttgggatggagtaggat 
ERBB2 -250 proximal promoter (ChIP) rev tccctaggctgccactctta 
HPRT1 (qRT-PCR) for tgaccttgatttattttgcatacc 
HPRT1 (qRT-PCR) rev cgagcaagacgttcagtcct 
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LSD1 (for cDNA synthesis) for atcctcgagagtgagcctgaagaacca 
LSD1 (for cDNA synthesis) rev aatctcgagtcacatgcttggggactg 
LSD1 (cloning of expression vector) for gccgaattcagtgagcctgaagaacca 
LSD1 (cloning of expression vector) rev aatctcgagtcacatgcttggggactg 
LSD1 (qRT-PCR) for gccatggtggtaacaggtct 
LSD1 (qRT-PCR) rev tggccagttccatatttacttg 
TFPI2 (qRT-PCR) for cgccaacaatttctacacctg 
TFPI2 (qRT-PCR) rev ggcaaactttgggaacttttt 
TFPI2 proximal promoter (ChIP) for gcaggtcatttccgtctagc 
TFPI2 proximal promoter (ChIP) rev acctgcctcccaaactttct 
TPM1 (qRT-PCR) for ccacgctctcaacgatatga 
TPM1 (qRT-PCR) rev cagagaggtgggacatccag 
TNS1 (qRT-PCR) for ccccaatgagccaaacttc 
TNS1 (qRT-PCR) rev gggatgatggagtgctggta 
XRCC5 (qRT-PCR) for cccaaatcctcgatttcaga 
XRCC5 (qRT-PCR) rev cccggggatgtaaagctc 
XRCC5 -300 proximal promoter (ChIP) for caatgagagaaaagggacgtg 
XRCC5 -300 proximal promoter (ChIP) rev ctctccattccgccgtagt 
 
 
7.1.9.   Bacterial strains 
 
These bacteria were used for the transformation of recombinant plasmids. 
 
DH5α (Invitrogen, Karlsruhe) F-, φ80lacZ∆M15, ∆(lacZYA-argF)U169, recA1, endA1, hsdR17(rk-, 
mk+), phoA, supE44, thi-1, gyrA96, relA1 and tonA 
 
TOP10 (Invitrogen, Karlsruhe) F-, mcrA, ∆(mrr-hsdRMS-mcrBC), Φ80lacZ∆M15, ∆lacX74, recA1, 
araD139, ∆(araleu)7697, galU, galK, rpsL, (StrR),endA1 and nupG. 
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7.1.10.   Cell lines 
 
Table 7.3. Description and origin of cell lines used in this work 
 
 Description Source 
BE2C Human neuroblastoma cells Institute of Pathology 
IMR Human neuroblastoma cells Institute of Pathology 
Kelly Human neuroblastoma cells Institute of Pathology 
LAN1 Human neuroblastoma cells Institute of Pathology 
MDA-MB 231 Human breast cancer cells Institute of Pathology 
MDA- MB 453 Human breast cancer cells Institute of Pathology 
MCF7 Human breast cancer cells Institute of Pathology 
NB69 Human neuroblastoma cells Institute of Pathology 
SHEP Human neuroblastoma cells Institute of Pathology 
SH-SY5Y Human neuroblastoma cells Institute of Pathology 
SKNAS Human neuroblastoma cells Institute of Pathology 
T47D Human breast cancer cells Institute of Pathology 
 
 
7.1.11.   Human breast specimens 
Human breast cancer speicimens of different stages were collected for my study. 38 human 
breast cancers, matched pairs of normal and malignant tissue, were stored at -80 in our tumor 
bank (Institute of Pathology, Bonn). All tumor samples were evaluated by a panel of experienced 
pathologists for histopathological staging according to UICC TNM system (TNM stand for Tumor, 
Nodes and Metastases). The diagnosis was confirmed histologically in all cases, based mainly on 
examination of sections stained with Haematosilin and Eosine (HE). 
 
7.2.   Buffers and solutions 
 
7.2.1.   Bacterial culture 
 
Luria Bertani (LB) medium Bactotryptone 1% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 0.5% (w/v) 
 
pH was adjusted to 7.5 with NaOH and then solution was 
autoclaved. 
 
Luria Bertani (LB) 1.5% agar Bactotryptone 1% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 0.5% (w/v) 
Agar 1.5% (w/v) 
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The pH was adjusted to 7.5 with NaOH. The solution was 
autoclaved, cooled to 50°C and the corresponding antibiotics 
(30 µg/ml Ampicillin) were added. Approximately 25 ml medium 
were poured per petridish and allowed to solidify. Plates were 
then packed under sterile conditions and stored at 4 °C until 
use. 
 
 
7.2.2.   Cell culture 
 
DMEM Medium Invitrogen, Karlsruhe 
DPBS Invitrogen, Karlsruhe 
FCS Invitrogen, Karlsruhe 
RPMI 1640 Medium Invitrogen, Karlsruhe 
Trypsin/EDTA (0.05% / 0.01%) Invitrogen, Karlsruhe 
10 % DMEM/RPMI 10 % (v/v) FCS, 1 % (v/v) Penicillin/streptomycin in DMEM 
0.5 % DMEM/RPMI 0.5 % (v/v) FCS, 1 % (v/v) Penicillin/streptomycin in DMEM 
 
 
7.2.3.   Protein expression & purification 
 
Elution buffer 300 mM Imidazole, 10 mM Tris pH 8.0 
HiTrap Ion exchange column buffer 50 mM Tris pH 8.0 
IPTG 100 mM in water 
Lysis & Washing buffer 20 mM Imidazole in 2x PBS 
Size exclusion chromatography buffer 100 mM NaCl, 10 mM Tris pH 8.0 
Storage buffer 100 mM NaCl, 5 % Glycerol, 20 mM Tris pH 8.0 
 
 
7.2.4.   Western blotting 
 
10% APS (w/v) 1g Ammonium peroxysulfate in 10ml water 
Acrylamide solution 38 % acryamide, 2 % bisacrylamide 
Coomassie staining 0.1 % Coomassie Brilliant Blue R250 
25 % methanol, 10 % acetic acid 
5x Electrophoresis buffer  0.125M Tris, 0.96 M Glycine, 0.5% SDS in DDW 
Lysis buffer for protein 
preparation (RIPA) 
150 mM NaCl, 0.5 % Na-Deoxycholate, 1 % NP-40, 0.1 % SDS, 
50 mM Tris pH 7.5, 1x complete mini 
4x Protein loading buffer 200 mM Tris HCl, pH 6.8,  SDS 8% (w/v), Glycerol 40% (v/v), 
Bromophenol blue 0.01% (w/v), 1 M DTT 40% (v/v) 
SemiDry Transfer buffer 48 mM Tris, 39 mM Glycine, 1.3 mM SDS, Methanol 5 % (v/v)  
12% Separating gel buffer Tris HCl, pH 8.8 375 mM, SDS 0.1% (w/v), Acrylamide 12% (w/v), 
Bisacrylamide 0.24% (w/v), Ammonium persulphate 0.1% (w/v), 
TEMED 0.1% (v/v) 
5% Skim milk in PBST 5 % skim milk, 0.05 % Tween 20, in PBS 
5% Stacking gel buffer Tris HCl, pH 6.8 187.5 mM, SDS 0.1% (w/v), Acrylamide 5% 
(w/v), Bisacrylamide 0.1% (w/v), Ammonium persulphate 0.1% 
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(w/v), TEMED 0.1% (v/v) 
Wash buffer 1x PBST 
 
 
7.2.5.   DNA/RNA techniques 
 
6x Sample buffer Glycerol 50% (v/v), EDTA 0.002 mM, Bromo phenol blue 0.0025% (w/v), 
Xylene cyanol 0.0025% (w/v) 
6x Sample buffer Glycerol 50% (v/v), EDTA 0.002 mM, Orange G 0.0025% (w/v) 
Solution I 50 mM Tris-HCl, pH 8.0, 10 mM EDTA 
Solution II 0.2 N NaOH, 1.0% SDS 
Solution III 3 M KOAc, pH 4.8  
[60 ml 5 M KOAc, 11.5 ml HOAc, 28.5 ml H2O] 
TAE (50x) 2 M Tris acetate, 50 mM EDTA (pH 8.0) 
TBE (10x) 108 g Tris, 55 g boronic acid in 40 ml EDTA 
TE buffer 10 mM Tris-Cl, 1 mM EDTA (pH 7.5.) 
 
 
7.3.   Cell culture techniques for mammalian cells 
 
7.3.1.   Mammalian cell culture method  
All cell lines were cultivated at 37°C in an incubator with 5% CO2 and humid atmosphere. 
Adherent growing cells were grown in tissue culture dishes on 6, 10 or 15 cm diameter dishes. 
The growth medium was renewed as required. Antibiotic mixtures of penicillin and streptomycin 
(Pen/Strep) were used to minimize bacterial contamination. 
 
Almost confluent (80-90%) grown cells were passaged into a new culture dish. First the medium 
was removed and cells were washed with 10 ml PBS. Approximately 1 ml of a trypsin/EDTA 
solution (Invitrogen) was added and the plate was incubated at 37°C for 3-5 min to dislodge the 
cells. Trypsinization was inhibited by addition of 10 ml growth medium. Cells were mixed well by 
pipetting up and down with a 10 ml glass pipette and resuspended in growth medium and seeded 
at suitable density. 
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7.3.2.   Freezing and thawing of mammalian cells 
A 15 cm confluent culture dish was passaged as above. Cells were resuspended in 5 ml freezing 
medium with 10% DMSO and transferred with a sterile 1 ml pipette in cryotubes. The cells were 
stored overnight at –20°C prior to -170°C long term storage. 
 
Cells were thawed in a 37°C waterbath as quickly as possible. In order to minimize the toxic 
effect of the DMSO, 5 ml fresh growth medium were added and cells were pelleted by 
centrifugation at 1,200 rpm for 2 min. The cell pellet was resuspended in the appropriate cell 
culture medium and seeded depending upon desired cell density in tissue culture dishes and 
cultivated under standard conditions. 
 
 
7.3.3.   Treatment of adherent cells with siRNAs 
Cells were seeded with 1x105 cells in 24 well plates, then incubated for 3 - 12 days in standard 
medium in the presence of 10- 20 nM siRNA directed against LSD1 (targeted on exon 8; Ambion, 
Austin, USA) or control siRNA (scrambled) complexed with HiPerFect Transfection Reagent 
(Qiagen) according to the manufacturer´s instructions. 
 
 
7.3.4.   Treatment of adherent cell with MAOIs 
Cells were seeded at a density of 2x104 cells in 96 well plate, and cultured in standard medium. 
Treatment with clorgyline (Sigma-Aldrich, Hamburg, Germany), pargyline (Fluka, Hamburg, 
Germany) or tranylcypromine (Biomol, Hamburg, Germany) was accomplished in  0.5 % DMEM 
or RPMI as indicated. 
 
 
7.3.5.   MTT cell proliferation assay 
MTT (0.12 mg/ml) was added in an amount equal to 10 % of the culture medium volume and cells 
were incubated for 2-4 hours. After the incubation, culture mediums were removed and 100 µl 
DMSO were added and absorbance was measured at a wavelength of 570 nm. 
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7.4.   DNA techniques 
 
7.4.1.   Photometric measurement of nucleic acid concentration 
To determine the concentration of DNA or RNA in a solution the optical density (OD) was 
measured. Nucleic acids have an absorption maximum at 260 nm and proteins absorb UV light 
maximally at a wavelength of 280 nm. Pure DNA exhibits an OD 260/OD 280 ratio of up to 2. This 
ratio is inversely proportional to the amount of proteins present in the solution.  
For pure nucleic acids: 1 OD 260 corresponds to a concentration: 
dsDNA: 50 µg/ml 
Oligonucleotide: 20 - 30 µg/ml 
ssDNA: 33 µg/ml 
RNA: 40 µg/ml 
 
A nanodrop spectrophotometer was used for quantification of DNA and RNA. 
 
 
7.4.2.   Plasmid DNA isolation (mini/maxi preparation) 
For mini preparation, 2 ml of overnight culture was centrifuged at 13,000 rpm for 1 minute. 
Supernatant was aspirated and cell pellet was resuspended in 300 µl Solution I (50 mM Tris-HCl, 
pH 8.0, 10 mM EDTA). Solution II 300 µl (0.2 N NaOH, 1.0% SDS) was added and mixed gently 
by inversion. Solution III 300 µl (3 M KOAc, pH 4.8 [60 ml 5 M KOAc, 11.5 ml HOAc, 28.5 ml 
H2O]) was added and vortexed briefly to mix, and centrifuged for 5 minutes on high. Supernatant 
was transferred to fresh tube containing 0.7 volumes isopropanol and vortexed and spun for 5 
minutes on high. Pellet was washed with 500 µl 75% ethanol, spin for 1 minute. Ethanol was 
removed as much as possible and DNA pellet was dried by leaving tubes on bench with lids open 
for ~5 minutes. DNA was resuspend in 40 µl of 20 µg/ml RNase A H2O. 
For maxi preparation, 100 ml - 500 ml of overnight bacterial culture was used. The plasmids were 
isolated with silica columns according to manufacturer's instructions (Midi/Maxi kit, Qiagen). 
 
 
7.4.3.   Separation of DNA by agarose gel electrophoresis 
Agarose gel electrophoresis was used to resolve DNA constructs. Agarose gels (1 %) were 
casted in TAE Buffer. Ethidium bromide was added to the gel (final concentration 0.5 µg/ml).  
DNA samples were diluted in 5x loading dye before loading on agarose gels. One kb and 100 bp 
molecular weight ladders (Invitrogen) were used to analyze the molecular size of the DNA. Gels 
were run at 80 V in TAE buffer for about 1 hour. DNA on gels was viewed under UV illumination 
using a digital imaging system (Intas UV system). 
 
 
 
 
Materials and methods 
 
 78 
7.4.4.   Extraction of DNA from agarose gels 
Under UV-light desired bands were removed from the gel using a sterile scalpel. DNA was 
extracted from the agarose using the QIAquick gel extraction kit (Qiagen). 
 
 
7.4.5.   DNA precipitation in ethanol/isopropanol  
Ethanol and isopropanol precipitation was used for the purification of DNA and RNA. Ionic 
concentration of the aqueous DNA and/or RNA solution was increased by addition of 1/10 volume 
3 M sodium acetate solution (pH 5.2). About 2.5 times volumes of ethanol/isopropanol were 
added. The DNA and/or RNA was incubated at -20°C for 30-60 min. Afterwards the sample was 
centrifuged at 13,000 rpm, the pellet was washed with 70% ethanol and dried for 10 min at 60°C. 
Then the DNA and/or RNA pellet was dissolved in the desired quantity of milli Q water or TE 
buffer (10 mM Tris-Cl, 1 mM EDTA, pH 7.5.). 
 
 
7.4.6.   Enzymatic restriction of plasmids 
Digestions of DNA with restriction endonucleases were performed according to the instructions 
given by the manufacturer (New England BioLabs). 
 
 
7.4.7.   Dephosphorylation of DNA fragments 
Vectors that were digested with restriction endonucleases have two compatible ends that can self 
ligate. In order to minimize such ligations and to increase the cloning efficiency, the 5’-phosphate 
group of the linearized vectors was removed by an alkaline phosphatase from the shrimp (New 
England BioLabs). Linearized vectors (1 µg) were treated with 1 U of shrimp alkaline 
phosphatase SAP for 30 min at 37°C. Prior to addition of insert DNA for ligation, 
dephosphorylation reactions were terminated by heat inactivation at 65°C for 15 min. 
 
 
7.4.8.   Ligation of DNA fragments 
Purified linearized vector (0.01 – 0.2 µg) and PCR product were used in a molar ratio of 1:2 or 1:3 
respectively. Using T4 ligase (5 U/µl, Invitrogen), the ligation reaction was carried out according 
to the instructions supplied by the manufacturer. The ligation reaction volume (5-10 µl) was used 
for transformation of competent E. coli. 
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7.4.9.   Ligation of PCR products/TOPO cloning 
PCR products were ligated with the TOPO® TA cloning kit (Invitrogen). To avoid auto 
degradation of adenosine overhangs upon longer storage intervals, freshly prepared PCR 
products were used. The ligation was done according to the manufacturer's directions. 
 
 
7.4.10.   Transformation and selection 
The ligation product (1- 10 µl) was mixed with 100 µl of competent E. coli (DH5 α or Top 10) and 
incubated on ice for 30 min. Next the cells were heat shocked at 42°C for 40s and were quickly 
placed on ice for 2 min. 1 ml LB or SOC medium was added and cells were incubated in a 
bacterial shaker at 37°C with for 1 h. Tubes were then centrifuged for 1 min at 12,000 rpm. The 
pellet was resuspended in 50- 200 µl of respective medium and cells were streaked on LB-plates 
with respective antibiotic. After 14-20 h of incubation at 37°C, colonies were chosen and kept for 
overnight cultures in 5 ml LB-growth medium with the respective antibiotic. 
 
 
7.4.11.   Cloning of LSD1 expression construct 
cDNA comprising the coding sequence of the human LSD1 (166–852aa) were made from pCMX-
flag LSD1 vector (gift from Prof. R. Schüle) by PCR using primers (forward primer: 5’-
gccgaattcagtgagcctgaagaacca-3’, reverse primer: 5’- aatctcgagtcacatgcttggggactg-3’). Restriction 
sites for XhoI was incorporated in the sense and antisense primers, in order to facilitate 
subsequent cloning. The PCR amplicon was subcloned into the cloning vector pCR2®II-TOPO 
and then the cDNA was subcloned into XhoI sites of pET-15b expression vector.   
 
 
7.4.12.   Sequencing of DNA 
The DNA sequence of plasmids was performed by Entelechon (Regensburg). 
 
 
7.4.13.   Sequence analysis  
The DNA sequence for the LSD1 gene (166 -852 aa) was analyzed using the sequence 
alignment tool in NCBI homepage.  
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7.4.14.   PCR: in vitro amplification of DNA  
DNA sequence for the respective gene was obtained from the NCBI web site. 
 
Primers for PCR were designed based on the following general considerations: the length of the 
primer should be around 19 bp, the melting temperature (Tm) of the primer should be close to 
60°C, and the nucleotide at the 3’ end should be either G or C. Primers used in the same PCR 
reaction were checked carefully to avoid formation of primer-primer dimers. 
 
The melting temperature of the primer was calculated according to the following formula: 
Tm = 4 (G+C) + 2 (A+T) 
 
PCR reactions were performed in a total volume of 50 µl.  
 
Detail End concentration 
DNA template (cDNA, plasmid DNA) 2 ng/µl  
Primer sense 0.3 µM 
Primer antisense 0.3 µM 
Taq DNA polymerase 10x buffer 1x 
MgCl2 2 mM 
dNTPs 25 nM 
Taq DNA polymerase 1 U 
Made upto 50 µl with milli Q water 
 
The reaction parameters (temperature, cycle) were adapted to the respective PCR setup. 
 
The standard PCR program consists of the following steps: 
 
1)  Initial denaturation                  94°C                 5 min 
2)  Denaturation                           94°C                45 sec 
3)  Annealing                               50–60°C          45 sec             
4)  DNA synthesis (extension)     72°C                 2 min 
5)  20-35 Cycles of 2-4) 
6) Terminal DNA-Synthesis         72°C               10 min 
7) Cooled at 4°C. 
 
 
7.4.15.   Purification of PCR-Products 
PCR products were cleaned up over spin columns in accordance to the manufacturer´s datasheet 
(Qiagen). 
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7.4.16.   Real-time RT-PCR 
Total RNA was isolated from cells using the RNeasyMini kit (Qiagen), and cDNA synthesis was 
performed using the SuperScript Reverse Transcription Kit (Invitrogen). Gene expression was 
monitored by quantitative real-time PCR (Applied Biosystems). SYBR GreenER qPCR SuperMix 
for ABI PRISM (invitrogen) was used with ABI real-time instrument (ABI7900HT). Expression 
values were normalized to the mean of 18s rRNA. 
 
PCR reactions were performed in a total volume of 20 µl.  
 
Detail End concentration 
DNA template (cDNA) 0.5 – 4 µl (cDNA generated from up to 1 µg of RNA  
Primer sense 200 nM 
Primer antisense 200 nM 
SYBR GreenER qPCR SuperMix 1x 
DEPC-treated water                                   to 20 µl 
 
The standard real-time RT-PCR program consists of the following steps: 
       50°C for 2 minutes hold  
       95°C for 10 minutes hold  
       40 cycles of: 
           95°C, 15 seconds 
           60°C, 60 seconds    
       Followed by melting curve analysis                                         
 
 
7.4.17.   Chromatin Immunoprecipitaiton  
Cells were transfected 3-6 days before harvesting for Chromatin immunoprecipiation (ChIP) with 
or without LSD1 siRNA (Ambion) following the manufacturer's instructions. Immunoprecipitation 
was performed with specific antibodies to H3K4me2 (Abcam), H3K9me2 (Abcam) and LSD1 
(Novus Biologicals) on protein A coupled Dynabeads (Invitrogen). Purified DNA were subjected to 
real-time PCR using a SYBR green probe (Invitrogen) in an ABI Prism 7900 (Applied Biosystems), 
according to the manufacturer’s specified parameters. Amplicons were normalized to the 1/100 
diluted input DNA or to the DNA immunoprecipitated with antibody to histone H3 (Abcam). The 
following TaqMan real-time PCR primers were used for the proximal promoter region of TFPI2, 
XRCC5, CCNA2 and ERBB2 are listed in table 7.2.   
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7.5.   RNA techniques 
 
7.5.1.   Isolation of RNA 
Total RNA from adherent cells was isolated from cell using RNeasyMini kit according to 
manufacturer's instructions (Qiagen). The RNA concentration was estimated using the Nanodrop. 
 
 
7.5.2.   Reverse transcription/cDNA synthesis 
About 1-5 µg of RNA were used for cDNA synthesis and volume was adjusted to 10 µl with DEPC 
water. One µl of oligo (dT) primer was added to RNA and mixture was incubated at 60°C for 5 
min. In the meantime, master mix was prepared as follows: 1 µl DEPC water, 1 µl 10 mM dNTPs, 
4 µl 5x first strand buffer, 2 µl 0.1 M DTT and 1 µl reverse transcriptase. Nine µl of master mix 
was added to each tube and tubes were incubated at 42°C for 1 h followed by 15 min incubation 
at 70°C for cDNA synthesis.  
 
 
7.6.   Protein techniques 
 
7.6.1.   Preparation of protein samples from adherent cells 
Cells were washed and scrapped off in ice cold PBS. Cells were pelleted by centrifugation at 
1,000 rpm/ 5 min/ 4°C and lysed with RIPA buffer (200 µl for 6 cm dish and 400 µl for 10 cm dish) 
on ice for 30 min in the presence of protease inhibitor mix. The lysates were cleared by 
centrifugation at 12,000 rpm.  
 
 
7.6.2.   Preparation of protein samples from tissues 
20-50 mg tumor tissues from patients were homogenized using FastPrep kit (MP biomedicals) by 
homogenating 3 x 5 min in FastPrep FP120 instrument (MP Biomedicals). Following centrifuge, 
the supernatant in 200 – 500 µl of RIPA lysis buffer in the presence of the complete mini protease 
inhibitor cocktails (Roche) was transferred to a new tube and one aliquot was used for protein 
measurement. 
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7.6.3.   Tissue preparation – Cryosectioning 
The prepared tumor tissues were sectioned in the cryostat (CM 3050 S, Leica) at a temperature 
of -18 to -24°C to a thickness of 12-20 µm. After cutting, the sections were dried for 10-15 min at 
room temperature and prepared for the HE staining.  
 
 
7.6.4.   Hematoxylin and Eosin (HE) staining 
Cryosections of tumor tissues were incubated in 1% Hematoxylin solution for 3 min. Slides were 
then washed 10 min with milli Q water, followed by eosin staining in 0.1% Eosin solution for 1 min. 
Slides were then wahed with increasing gradient of ethanol (80%-100%) prior to incubating 2X5 
min with Xylol solution. Excessive xylol was removed with clean tissue paper and slides were 
covered with Roti Histo-Kit II (Roth) mounting medium and dried. Microscopic visualization of 
slides was done using digital-camera KY-F70B (JVC, London) connected to microscope Axioskop 
50 (Zeiss). 
 
 
7.6.5.   Immunohistochemistry 
Tissue slides were cut 4 µm thick from formalin-fixed and paraffin embedded human colon cancer 
or breast cancer specimens and used for staining with haematoxilin and eosine (HE) or by 
immunohistochemistry. Indirect immunohistochemistry was done by the avidin-biotin-method. 
Tissue sections were incubated overnight at 60°C, deparaffinized for 10 min in xylene, then 
washed for 5 min with 100 %, 96 %, 70 %, 50 % ethanol and finally washed in PBS. For better 
antigen retrieval, samples were boiled in a microwave oven in citrate buffer pH 6.0 (Merck) for 15 
min. Then samples were washed in PBS.  
 
The samples were incubated for 1 h at RT with the primary antibodies diluted in blocking buffer 
(DAKO) by using the TechMate 500 semiautomatic machine (DAKO). Slides were incubated 
overnight with LSD1 primary antibody diluted 1:250. After slides were washed twice for 5 min in 
PBS, a horseradish peroxidase /HRP)-labelled polymer conjugated with a secondary antibody 
was applied (Dako EnVision AEC kit). After 2x washing with PBS, slides were treated with 
endogenous peroxidase for 5 min in (0.03 % H2O2). The staining was visualized with 3-amino-9-
ethyl-carbazolke (DAKO) and after a final washing step. Slides were counterstained with Mayer´s 
hematoxylin (Fluka), dehydrated and mounted by using Aguatex (Merck). Negative controls were 
performed using blocking solution alone instead of the primary antibody diluted in blocking 
solutions and resulted in complete absence of signal. 
 
Nuclear immunostaining results for LSD1 were evaluated using a semi-quantitative scoring 
system. Briefly, the number and intensity of positive cells were counted and scored between 0 
and 3 (0 = no positive nuclei, 1 = < 20% nuclei display intense staining or more nuclei display 
weak staining, 2 = 20-80% intense staining, or more nuclei display moderate staining, 3 = 80-
100% nuclei display intensive staining).  
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Tissue images were taken by using a microscope (Leica) and by using the analysis system 
software Diskus (Hilgers). 
 
 
7.6.6.   Protein quantification 
The method developed by Bradford was employed using coomassie blue dye (Bio-Rad protein 
assay) and BSA, bovine serum albumin as standard. In the range between 1.2 and 10 µg/ml, the 
protein concentration can be determined photometrically according to the Lambert-Beer law.  Ten 
µl of standards or 1 µl protein sample are added to 200µl of Bradford reagent diluted 1:4 in PBS. 
Absorption measurements and calculation of sample concentrations are carried out 
photometrically on an ELISA reader (Biotek instrument). 
 
 
7.6.7.   Protein staining with Coomassie Brilliant Blue R250 
Gel was washed thoroughly with H2O and stained with Coomasie Blue for at least 30 minutes to 
1 hr. Gel was incubated with the Destain solution, until the background is gone and blue bands 
are clearly visible. 
 
 
7.6.8.   SDS-PAGE/Western blot 
About 10 – 50 µg of protein samples were loaded in polyacrylamide gel and gel was run (25 mA 
per gel) in 1x SDS running buffer. After electrophoresis, proteins from a polyacrylamide gel were 
transferred to a PVMF membrane using blotting chamber (BioRad). Membrane was blocked with 
5% skim milk in PBST for 1 h or overnight at 4°C. The blot was then incubated with appropriately 
diluted primary antibody solution for 1 h at room temperature. The following antibodies and 
dilutions were used: α-LSD1 (Novus Biologicals) 1:1000; α-H3K4me2 (Abcam) 1:1000; β-actin 
(Sigma-Aldrich) 1:5000; Her2/erbB2 (DAKO), 1:1000. The blots were washed 3 times each for 5 
min with PBS-T and later incubated with appropriate secondary antibody conjugated to HRP 
(Horseradish peroxidase) for 1 h at RT. The blots were again washed with PBST and 
chemiluminescent peroxidase substrate was used to visualize protein bands.In the dark, X-ray 
film was exposed to the membrane and developed using Kodak X-omat 1000 Processor (Kodak). 
Coomassie staining was used as a loading control in some experiment, since the frequently used 
reference protein ß-actin was clearly up-regulated in the cancer specimen. 
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7.6.9.   ELISA 
For ELISA analysis, 20 normal breast tissues, 26 ER-positive and 37 ER-negative breast tumor 
tissues were used. Hematoxylin-eosin-stained sections were prepared for assessment of the 
percentage of tumor cells; only samples with >70% tumor cells were selected.  
 
96-well Maxisorb microplates (Nunc, Wiesbaden, Germany) were incubated with tissue protein 
lysates (40 µg) in coating buffer (50 mM sodium carbonate buffer, pH 9.2) overnight at 4 °C. After 
removal of the coating solution by inverting the plate, the wells were blocked with 200 µl blocking 
buffer (Roche, Mannheim, Germany) for 1 h at room temperature. After rinsing with washing 
buffer (0.05 % Tween in PBS, PBS-T), the wells were incubated with α-LSD1 solution (1: 400, 
Novus Biologicals, Cat. No NB 100-1762) in 100 µl blocking buffer for 1 h at 25 °C followed by 
three washing steps with 200 µl PBS-T. After addition of 100 µl HRP-labelled α-mouse (1:1000, 
DAKO, Glostrup, Denmark, Cat. No. P-0448), the wells were incubated for 0.5 h and washed 
three times. Finally, 100 µl of the TMB substrate solution (1 Step Ultra TMB, Thermo Scientific, 
Rockford, USA) were added to each well. The conversion of substrate was stopped by addition of 
100 µl of 2 N sulphuric acid solution. The optical density was determined in an ELISA reader 
(ELX 800 Universal, Biotek Instruments, Winooski, USA) at 450 nm. 
 
For standard curve, microplates were incubated with a series of dilution of recombinant  6x his-
tagged LSD1 protein (1.0, 3.1, 9.3, 27.8, 83.3 and 250.0 µg/L) and breast tumor tissue protein 
lysate (3, 10, 30 and 60 µg/well) in coating buffer (50 mM sodium carbonate buffer, pH 9.2) 
overnight at 4 °C.  Antibody dilution ratio was modified for the recombinant LSD1. (α-LSD1, 
1:4000; HRP-labelled α–mouse, 1:1000). Otherwise, all steps were performed as described 
above.  
 
 
7.6.10.   Expression and purification of recombinant human LSD1  
Genes encoding LSD construct (166 – 852 amino acids) was inserted into the vector pET15b 
(Novagen). The final construct is missing the first 165 amino acid but N-terminal his6-tagged 
LSD1 ∆N (166-852) still contains the SWIRM and amino oxidase domains, which has previously 
been shown to have a enzyme activity toward peptide substrate in vitro (FEBS lett. 579,2203, 
2005).   
 
E. coli BL21 (DE3) Star was transformed with LSD1 expression vector and colonies were 
inoculated directly to 3L Terrific Broth, grew at 37C until saturation. The expression vector 
contains the promoter of the lac-operon, so that the expression of the recombinant gene can be 
induced by the synthetic lactose analogon IPTG (isopropylthio- galactopyranoside). Protein 
expression is induced by addition of 100 mM IPTG solution (final concentration 0.75 – 1 mM 
IPTG) and incubated overnight at 20 °C. Samples are taken prior to and after induction and 
analyzed by SDS-PAGE.  
 
Cells were harvested and lysed with 2X PBS buffer containing 20 mM Imidazole. The lysate was 
applied to Ni2+ affinity column (Gravity column) and washed with lysis buffer. His-tagged LSD1 
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protein was eluted with elution buffer (100 mM Tris-HCl pH 8.0, 300 mM Imidazole). The protein 
was concentrated to 4 ml and then purified on a Superdex 200 (16/60) size exclusion 
chromatography (GE Healthcare, Piscataway, U.S.A.) in 20 mM Tris-HCl pH 8.0, 100 mM NaCl. 
Three fractions were passed through HitrapQ ion exchange column (50 mM Tris pH 8.0). Finally, 
purified N-terminal his6-tagged LSD1 ∆N (166-852) was stored in 20 mM Tris-HCl pH 8.0, 100 
mM NaCl, 5 % Glycerol. The protein yield was estimated ~ 1mg/L. 
 
 
7.6.11.   LSD1 enzyme assay for high-throughput screening 
Peroxide production by LSD1 was monitored using a HRP coupled assay (Forneris, 2005, JBC; 
Forneris, 2005, FEBS Lett) with exception that Amplex red (100 µM) was used as the fluorogenic 
electron donor in fluorescene-based assays.  
 
The demethylase activity of N-terminal his6-tagged LSD1 ∆N (166-852) was assayed with 
synthetic peptide corresponding to the first 24 amino acids of N-terminal tail of histone H3, 
incorporating dimethylated Lys at residue 4 (H3K4me2; CASLO, Lyngby, Denmark). The total 
LSD1 assay volume was 40 µl and all the assay components were diluted in HEPES buffer (50 
mM HEPES/NaOH pH 7.4, 0.1% Triton X100). The reaction was carried out in white 96-well 
plates (Costar 3693). In brief, reaction was started by adding peptide substrate (50 µMl) to the 
LSD1 assay mixture contained LSD1 (0.25 µM), inhibitor (0.4, 2, 10, 50 µM), Amplex red (100 
µM) and HRP (0.4 µM). Concentrations represent the end-concentration of the reagents. Positive 
controls contained all the above components except the inhibitor. The negative controls contained 
neither substrate nor inhibitor. In each case, these were replaced with an equivalent volume of 
buffer. The assay components were incubated at 37 °C for 30 min to obtain progress curves. The 
fluorescence generated was monitored at wavelengths 560 nm (excitation) and 590 nm 
(emission) in the plate reader (BMG LABTECH´s FLUOstar OPTIMA, Offenburg). The linear 
range for LSD1 was determined (0.05 - 1 µM), resulting in the use of final concentration of 0.25 
µM LSD1.  
 
For assessment of inhibition of LSD1, the Km for the dimethylated peptide substrate (H3K4me2) 
was assayed and found to be 35 µM. The use of Km reflects the conversion of dimethylated 
substrate to unmethylated product via two demethylation events. This substrate concentration 
was then used in all subsequent inhibition assays.  
 
Inhibitos were prepared as 10 mM stocks in diemethyl sulfoxide (DMSO) and stored at -20 °C. 
IC50 value was determined by preincubating LSD1 with varying concentrations of inhibitor for 5 
min at room temperature prior to initiation of the reaction via the addition of substrate. In control 
experiments, DMSO was found to have no effect on enzyme activity at concentrations used 
(2.5 %) (Data not shown). 
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7.6.12.   in vitro demethylase assay 
1 µg of N-terminal his6-tagged LSD1 ∆N (166-852) was incubated with 10 µg bulk histone in 50 
mM Hepes buffer pH 7.5 at for 3 hours 37 °C. The methlyation status of lys4 at histone H3 in bulk 
histone was analyzed using western blotting. 7 compounds were tested for their LSD1 inhibitory 
effect, while tranylcypromine served as a reference compound. Histone H3 was used as the 
loading control. α-H3K4me2 antibody was diluted 1:1000, while α-Histone H2 antibody was 
diluted in 1:10,000. 
 
 
7.7.   Growth of xenograft tumors in nude mice 
 
SH-SY5Y neuroblastoma cells were cultured to 80 % confluency, harvested, and suspended in 
Matrigel (BD Bioscience, Heidelberg, Germany). Four week-old female athymic NCR (nu/nu) 
mice were inoculated s.c. in the flank with 2 x 107 cells/ in 200µl Matrigel. Mice were injected with 
2mg tranylcypromine (in 100µl NaCl) or NaCl alone i.p. once per day. Mice were sacrificed at day 
21, and tumors were weighed, formalin fixed and analyzed.  
 
 
7.8.   Statistical methods 
 
Statistical significance of the ELISA results was tested by two-sided, non-parametrical Mann-
Whitney U-test to analyze differences in protein levels among distinct groups using SPSS 17.0 
program (SPSS, Inc., Zürich, Switzerland). Association between categorical variables was 
assessed by two-sided Fisher´s exact test using GraphPad Prism 5 (La Jolla, USA). 
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11.   Appendix 
 
 
Table. LSD1-HRP coupled assay, H2O2 interference test and in vitro demethylase assay   
 
LSD1-HRP coupled assay was performed using 4 different concentrations of 80 compounds. Some compounds were found to react directly with hydrogen 
peroxide, thus interfering with the LSD1-HRP coupled assay. To screen out the compounds reacting with hydrogen peroxide, exogenous hydrogen peroxide (5 
µM) was incubated with 50 µM compounds, 0.4 µM HRP and 100 µM Amplex red. The consumed hydrogen peroxide in the presence of the compounds was 
calculated.  
 
 
    LSD1-HRP coupled assay Reactivity of compounds to H2O2 in vitro demethylase assay 
No. Compounds No. Relative decrease of initial velocity Conc. of H2O2 reacting √§ Inhibition at 50 µM 
    50µM  10 µM 2 µM 0.4 µM to 50 µM compound (µM)   compound conc. 
  Tranylcypromine 0.34 0.53 0.52 0.35 0.00    LSD1 inhibitor 
1 P1 A11 0.60 0.72 0.19 1.12 0.06     
2 P1 A15 0.21 0.37 0.69 0.81 0.72     
3 P1 A21 n.d. 0.35 0.50 0.66 0.00 √   
4 P1 E11 0.30 0.39 0.45 0.48 1.87     
5 P1 E19 0.61 0.48 0.99 0.55 0.08 √   
6 P1 E21 n.d. 0.51 0.49 0.31 0.01 √   
7 P1 M19 n.d. 0.48 0.60 0.59 2.07     
8 P2 A1 0.26 0.50 0.67 0.60 0.00 √ LSD1 inhibitor 
9 P3 E15 0.26 0.19 0.40 0.36 2.29     
10 P3 G7 0.36 0.40 0.43 0.47 2.20     
11 P3 K21 n.d. 0.28 0.65 0.56 1.21     
12 P3 O1 0.42 0.39 0.39 0.33 2.37     
13 P4 A1 n.d. 0.48 0.48 0.68 0.17 √   
14 P4 A5 n.d. 0.62 0.72 0.62 0.40     
15 P4 A9 n.d. 0.25 0.64 0.60 0.03 √   
16 P4 A11 0.67 0.24 0.82 0.84 0.00     
17 P4 A15 0.29 0.43 0.69 0.77 0.55     
18 P4 A17 0.33 0.76 0.81 0.88 0.00     
19 P4 A19 0.74 0.77 0.82 1.01 0.00     
20 P4 A21 0.77 0.71 0.61 0.73 0.00     
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    LSD1-HRP coupled assay Reactivity of compounds to H2O2 in vitro demethylase assay 
No. Compounds No. Relative decrease of initial velocity Conc. of H2O2 reacting √§ Inhibition at 50 µM 
    50µM  10 µM 2 µM 0.4 µM to 50 µM compound (µM)   compound conc. 
21 P4 C1 0.30 0.85 0.94 0.83 0.00     
22 P4 C5 0.57 0.10 0.86 0.80 0.17     
23 P4 C9 0.50 0.77 0.74 0.58 0.70     
24 P4 C15 0.65 0.73 1.03 0.75 0.02     
25 P4 C17 0.67 0.83 1.07 1.03 0.00     
26 P4 C19 0.70 0.99 0.88 0.83 0.00     
27 P4 E1 0.73 0.79 0.98 0.78 0.00     
28 P4 E17 0.56 0.74 0.76 0.47 0.00     
29 P4 E19 0.68 0.94 0.86 0.20 0.00     
30 P4 E21 0.35 0.36 0.47 0.61 0.00 √   
31 P4 G1 0.40 0.38 0.40 0.51 0.17 √   
32 P4 G9 0.17 0.48 0.45 0.56 0.08 √   
33 P4 G11 0.37 0.61 0.76 0.55 0.03 √   
34 P4 G13 0.41 0.43 0.60 0.55 2.07     
35 P4 G15 0.53 0.61 0.61 0.65 1.04     
36 P4 G17 0.28 0.29 0.45 0.55 0.00 √   
37 P4 G19 0.24 0.39 0.49 0.47 0.00 √ inhibition 
38 P4 G21 0.19 0.17 0.15 0.16 0.13 √   
39 P4 I15 0.16 0.33 0.29 0.73 0.00 √   
40 P4 I19 0.60 0.90 0.87 0.97 0.00     
41 P4 I21 0.68 0.69 0.71 0.83 0.00     
42 P4 K1 0.66 0.77 0.99 1.02 0.00     
43 P4 K3 0.63 0.96 0.70 0.56 0.00     
44 P4 K19 0.39 0.54 0.74 0.82 0.05     
45 P4 K21 0.58 0.87 0.91 0.77 0.00     
46 P4 M21 0.76 0.27 0.83 0.72 0.00     
47 P4 O1 0.47 0.89 0.97 0.73 0.00     
48 P4 O5 0.61 0.89 0.95 0.87 0.00     
49 P4 O15 0.75 0.87 0.36 0.80 0.00     
50 P4 O21 0.53 0.79 0.85 0.18 0.00     
51 P5 E13 0.56 0.60 0.62 0.59 0.42     
52 P5 G9 0.43 0.85 1.04 0.82 0.03     
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    LSD1-HRP coupled assay Reactivity of compounds to H2O2 in vitro demethylase assay 
No. Compounds No. Relative decrease of initial velocity Conc. of H2O2 reacting √§ Inhibition at 50 µM 
    50µM  10 µM 2 µM 0.4 µM to 50 µM compound (µM)   compound conc. 
53 P5 M21 0.37 0.68 0.82 0.75 0.00     
54 P5 O11 0.06 0.25 0.49 0.47 0.00 √ inhibition 
55 P5 O17 0.11 0.44 0.47 0.80 0.13 √ inhibition 
56 P5 O21 0.22 0.33 0.18 0.35 0.27     
57 P6 A1 0.67 0.28 0.77 0.93 0.02     
58 P6A3 0.49 0.62 0.63 0.78 0.00 √ inhibition 
59 P6 A7 0.19 0.38 0.59 0.63 0.76     
60 P6 A11 0.10 0.47 0.62 0.29 1.24     
61 P6 A13 0.14 0.21 0.29 0.46 0.73     
62 P6 A15 0.36 0.48 0.51 0.50 0.00 √ inhibition 
63 P6 A17 0.31 0.68 0.96 1.05 0.16     
64 P6 A21 0.34 0.55 0.67 0.77 1.52     
65 P6 C7 n.d 0.45 0.58 0.56 0.15     
66 P6 C11 0.45 0.52 0.49 0.37 0.05 √   
67 P6 C17 0.33 0.34 0.41 0.32 1.58     
68 P6 E3 n.d 0.31 0.36 0.85 0.83     
69 P6 G5 0.58 0.67 0.69 0.67 0.00 √   
70 P6 G7 0.60 0.19 0.67 0.66 0.00 √   
71 P6 G19 0.17 0.35 0.53 0.60 1.20     
72 P6 I15 n.d 0.78 0.84 0.60 0.00     
73 P6 I19 0.81 0.72 0.86 0.74 0.00     
74 P6 K17 n.d 0.57 0.67 0.84 0.00 √   
75 P6 K19 n.d 0.15 0.71 0.91 0.00     
76 P6 M7 0.52 0.58 0.60 0.54 0.00 √   
77 P6 M13 0.40 0.32 0.40 0.32 1.40     
78 P7 A9 0.69 0.82 0.65 0.77 0.00     
79 P7 I19 0.47 0.71 0.85 0.75 0.00     
80 P8 K9 n.d 0.58 0.53 0.53 0.00 √ inhibition 
 
§ 24 compounds (√) which showed LSD1 inhibitory effect and didn’t´ react with H2O2 were selected for the further in vitro demethylase assay.  
 
n.d., not determind
